{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:37:12Z","timestamp":1773369432600,"version":"3.50.1"},"reference-count":339,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00508-026-02708-w","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:11:02Z","timestamp":1773328262000},"page":"11-48","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Konsensusempfehlungen zur Diagnose und Therapie der Hyperkali\u00e4mie der \u00d6sterreichischen Gesellschaft f\u00fcr Nephrologie 2026","Consensus recommendations on the diagnosis and treatment of hyperkalemia of the Austrian Society of Nephrology 2026"],"prefix":"10.1007","volume":"138","author":[{"given":"Gregor","family":"Lindner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Windpessl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Pirklbauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara H.","family":"Ksiazek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Edlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Saemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"2708_CR1","doi-asserted-by":"publisher","unstructured":"Clase CM, Carrero J\u2011J, Ellison DH, Grams ME, Hemmelgarn BR, Jardine MJ, u.\u202fa. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a\u00a0Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020;97:42\u201361. https:\/\/doi.org\/10.1016\/j.kint.2019.09.018","DOI":"10.1016\/j.kint.2019.09.018"},{"key":"2708_CR2","doi-asserted-by":"publisher","unstructured":"Cooper LB, Savarese G, Carrero J\u2011J, Szabo B, Jernberg T, Jonsson \u00c5, u.\u202fa. Clinical and research implications of serum versus plasma potassium measurements. Eur J Heart Fail. 2019;21:536\u20137. https:\/\/doi.org\/10.1002\/ejhf.1371","DOI":"10.1002\/ejhf.1371"},{"key":"2708_CR3","doi-asserted-by":"publisher","unstructured":"Stickle DF, Koob KR, McCudden CR. Characterizing ability of serum potassium\u00a0(K) and the serum K reference interval to flag hypokalemia or hyperkalemia as observed in plasma: A\u00a0simulation study. Clin Biochem. 2023;118:110606. https:\/\/doi.org\/10.1016\/j.clinbiochem.2023.110606","DOI":"10.1016\/j.clinbiochem.2023.110606"},{"key":"2708_CR4","doi-asserted-by":"publisher","unstructured":"Lindner G, Burdmann EA, Clase CM, Hemmelgarn BR, Herzog CA, Ma\u0142yszko J, u.\u202fa. Acute hyperkalemia in the emergency department: a\u00a0summary from a\u00a0Kidney Disease: Improving Global Outcomes conference. Eur J Emerg Med Off J Eur Soc Emerg Med. 2020;27:329\u201337. https:\/\/doi.org\/10.1097\/MEJ.0000000000000691","DOI":"10.1097\/MEJ.0000000000000691"},{"key":"2708_CR5","doi-asserted-by":"publisher","unstructured":"Varga C, K\u00e1lm\u00e1n Z, Szak\u00e1ll A, Drubits K, Koch M, B\u00e1nhegyi R, u.\u202fa. ECG alterations suggestive of hyperkalemia in normokalemic versus hyperkalemic patients. BMC Emerg Med. 2019;19:33. https:\/\/doi.org\/10.1186\/s12873-019-0247-0","DOI":"10.1186\/s12873-019-0247-0"},{"key":"2708_CR6","doi-asserted-by":"publisher","unstructured":"Raffee LA, Alawneh KZ, Ababneh MJ, Hijazi HH, Al Abdi RM, Aboozour MM, u.\u202fa. Clinical and electrocardiogram presentations of patients with high serum potassium concentrations within emergency settings: a\u00a0prospective study. Int J Emerg Med. 2022;15:23. https:\/\/doi.org\/10.1186\/s12245-022-00422-8","DOI":"10.1186\/s12245-022-00422-8"},{"key":"2708_CR7","doi-asserted-by":"publisher","unstructured":"Betts KA, Woolley JM, Mu F, McDonald E, Tang W, Wu EQ. The prevalence of hyperkalemia in the United States. Curr Med Res Opin. 2018;34:971\u20138. https:\/\/doi.org\/10.1080\/03007995.2018.1433141","DOI":"10.1080\/03007995.2018.1433141"},{"key":"2708_CR8","doi-asserted-by":"publisher","unstructured":"Mu F, Betts KA, Woolley JM, Dua A, Wang Y, Zhong J, u.\u202fa. Prevalence and economic burden of hyperkalemia in the United States Medicare population. Curr Med Res Opin. 2020;36:1333\u201341. https:\/\/doi.org\/10.1080\/03007995.2020.1775072","DOI":"10.1080\/03007995.2020.1775072"},{"key":"2708_CR9","doi-asserted-by":"publisher","unstructured":"Singer AJ, Thode HC, Peacock WF. A\u00a0retrospective study of emergency department potassium disturbances: severity, treatment, and outcomes. Clin Exp Emerg Med. 2017;4:73\u20139. https:\/\/doi.org\/10.15441\/ceem.16.194","DOI":"10.15441\/ceem.16.194"},{"key":"2708_CR10","doi-asserted-by":"publisher","unstructured":"Sarwar CMS, Papadimitriou L, Pitt B, Pi\u00f1a I, Zannad F, Anker SD, u.\u202fa. Hyperkalemia in Heart Failure. J\u00a0Am Coll Cardiol. 2016;68:1575\u201389. https:\/\/doi.org\/10.1016\/j.jacc.2016.06.060","DOI":"10.1016\/j.jacc.2016.06.060"},{"key":"2708_CR11","doi-asserted-by":"publisher","unstructured":"Bandak G, Sang Y, Gasparini A, Chang AR, Ballew SH, Evans M, u.\u202fa. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project. J\u00a0Am Heart Assoc. 2017;6:e005428. https:\/\/doi.org\/10.1161\/JAHA.116.005428","DOI":"10.1161\/JAHA.116.005428"},{"key":"2708_CR12","doi-asserted-by":"publisher","unstructured":"Parikh RV, Nash DM, Brimble KS, Markle-Reid M, Tan TC, McArthur E, u.\u202fa. Kidney Function and Potassium Monitoring After Initiation of Renin-Angiotensin-Aldosterone System Blockade Therapy and Outcomes in 2 North American Populations. Circ Cardiovasc Qual Outcomes. 2020;13:e006415. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.119.006415","DOI":"10.1161\/CIRCOUTCOMES.119.006415"},{"key":"2708_CR13","doi-asserted-by":"publisher","unstructured":"Marzano L, Merlo M, Martinelli N, Pizzolo F, Friso S. Efficacy and Safety of Aldosterone Synthase Inhibitors for Hypertension: A\u00a0Meta-Analysis of Randomized Controlled Trials and Systematic Review. Hypertens Dallas Tex 1979. 2025;82:e47\u201356. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.124.23962","DOI":"10.1161\/HYPERTENSIONAHA.124.23962"},{"key":"2708_CR14","doi-asserted-by":"publisher","unstructured":"Bakris GL, Saxena M, Gupta A, Chalhoub F, Lee J, Stiglitz D, u.\u202fa. RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA\u20111 Randomized Clinical Trial. JAMA. 2024;331:740\u20139. https:\/\/doi.org\/10.1001\/jama.2024.0728","DOI":"10.1001\/jama.2024.0728"},{"key":"2708_CR15","doi-asserted-by":"publisher","unstructured":"Desai AS, Karns AD, Badariene J, Aswad A, Neutel JM, Kazi F, u.\u202fa. Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA\u20112 Randomized Clinical Trial. JAMA. 2025;334:46\u201355. https:\/\/doi.org\/10.1001\/jama.2025.6681","DOI":"10.1001\/jama.2025.6681"},{"key":"2708_CR16","doi-asserted-by":"publisher","unstructured":"Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae D\u2011W, u.\u202fa. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. N Engl J Med. Massachusetts Medical Society; 2023;389:2436\u201345. https:\/\/doi.org\/10.1056\/NEJMoa2308550","DOI":"10.1056\/NEJMoa2308550"},{"key":"2708_CR17","doi-asserted-by":"publisher","unstructured":"Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae D\u2011W, u.\u202fa. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2\u2011year results from a\u00a0randomised, active-controlled, phase\u00a03\u00a0trial. The Lancet. Elsevier; 2023;402:2077\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(23)02302-4","DOI":"10.1016\/S0140-6736(23)02302-4"},{"key":"2708_CR18","doi-asserted-by":"publisher","unstructured":"Parving H\u2011H, Brenner BM, McMurray JJV, de Zeeuw D, Haffner SM, Solomon SD, u.\u202fa. Cardiorenal end points in a\u00a0trial of aliskiren for type\u00a02 diabetes. N Engl J Med. 2012;367:2204\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1208799","DOI":"10.1056\/NEJMoa1208799"},{"key":"2708_CR19","doi-asserted-by":"publisher","unstructured":"Hayes H, Russell R, Haugen A, Nagavally S, Sarvaideo J. The Utility of Monitoring Potassium in Transgender, Gender Diverse, and Nonbinary Individuals on Spironolactone. J\u00a0Endocr Soc. 2022;6:bvac133. https:\/\/doi.org\/10.1210\/jendso\/bvac133","DOI":"10.1210\/jendso\/bvac133"},{"key":"2708_CR20","doi-asserted-by":"publisher","unstructured":"SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293\u2013302. https:\/\/doi.org\/10.1056\/NEJM199108013250501","DOI":"10.1056\/NEJM199108013250501"},{"key":"2708_CR21","doi-asserted-by":"publisher","unstructured":"Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, u.\u202fa. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet Lond Engl. 2003;362:759\u201366. https:\/\/doi.org\/10.1016\/s0140-6736(03)14282-1","DOI":"10.1016\/s0140-6736(03)14282-1"},{"key":"2708_CR22","doi-asserted-by":"publisher","unstructured":"Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol CJASN. 2010;5:531\u201348. https:\/\/doi.org\/10.2215\/CJN.07821109","DOI":"10.2215\/CJN.07821109"},{"key":"2708_CR23","doi-asserted-by":"publisher","unstructured":"ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, u.\u202fa. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547\u201359. https:\/\/doi.org\/10.1056\/NEJMoa0801317","DOI":"10.1056\/NEJMoa0801317"},{"key":"2708_CR24","doi-asserted-by":"publisher","unstructured":"Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, u.\u202fa. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1009492","DOI":"10.1056\/NEJMoa1009492"},{"key":"2708_CR25","doi-asserted-by":"publisher","unstructured":"Whitlock R, Leon SJ, Manacsa H, Askin N, Rigatto C, Fatoba ST, u.\u202fa. The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a\u00a0systematic review and meta-analysis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2023;gfad101. https:\/\/doi.org\/10.1093\/ndt\/gfad101","DOI":"10.1093\/ndt\/gfad101"},{"key":"2708_CR26","doi-asserted-by":"publisher","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, u.\u202fa. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709\u201317. https:\/\/doi.org\/10.1056\/NEJM199909023411001","DOI":"10.1056\/NEJM199909023411001"},{"key":"2708_CR27","doi-asserted-by":"publisher","unstructured":"Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B, u.\u202fa. Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J\u00a0Am Coll Cardiol. 2012;60:2082\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2012.07.048","DOI":"10.1016\/j.jacc.2012.07.048"},{"key":"2708_CR28","doi-asserted-by":"publisher","unstructured":"Bakris GL, Ruilope LM, Anker SD, Filippatos G, Pitt B, Rossing P, u.\u202fa. A\u00a0prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type\u00a02 diabetes. Kidney Int. 2023;103:196\u2013206. https:\/\/doi.org\/10.1016\/j.kint.2022.08.040","DOI":"10.1016\/j.kint.2022.08.040"},{"key":"2708_CR29","doi-asserted-by":"publisher","unstructured":"Agarwal R, Joseph A, Anker SD, Filippatos G, Rossing P, Ruilope LM, u.\u202fa. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J\u00a0Am Soc Nephrol JASN. 2022;33:225\u201337. https:\/\/doi.org\/10.1681\/ASN.2021070942","DOI":"10.1681\/ASN.2021070942"},{"key":"2708_CR30","doi-asserted-by":"publisher","unstructured":"Idowu A, Lo KB, Adebolu O, Hamilton M, Abdelmaseeh P, Navaneethan SD, u.\u202fa. Hyperkalemia Risk of Finerenone Versus Spironolactone in CKD patients with type\u00a02 Diabetes. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2025;gfaf098. https:\/\/doi.org\/10.1093\/ndt\/gfaf098","DOI":"10.1093\/ndt\/gfaf098"},{"key":"2708_CR31","doi-asserted-by":"publisher","unstructured":"Jhund PS, Talebi A, Henderson AD, Claggett BL, Vaduganathan M, Desai AS, u.\u202fa. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet Lond Engl. 2024;404:1119\u201331. https:\/\/doi.org\/10.1016\/S0140-6736(24)01733-1","DOI":"10.1016\/S0140-6736(24)01733-1"},{"key":"2708_CR32","doi-asserted-by":"publisher","unstructured":"Agarwal R, Pitt B, Palmer BF, Kovesdy CP, Burgess E, Filippatos G, u.\u202fa. A\u00a0comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clin Kidney J. 2023;16:293\u2013302. https:\/\/doi.org\/10.1093\/ckj\/sfac234","DOI":"10.1093\/ckj\/sfac234"},{"key":"2708_CR33","doi-asserted-by":"publisher","unstructured":"Wang C\u2011A, Lai H\u2011W, Chen J\u2011Y, Wang W\u2011J, Lin L\u2011C, Chiu Y\u2011L, u.\u202fa. Finerenone versus spironolactone in patients with chronic kidney disease and type\u00a02 diabetes: a\u00a0target trial emulation. Nat Commun. 2025;16:9641. https:\/\/doi.org\/10.1038\/s41467-025-64640-3","DOI":"10.1038\/s41467-025-64640-3"},{"key":"2708_CR34","doi-asserted-by":"publisher","unstructured":"Floege J, Frankel AH, Erickson KF, Rtveladze K, Punekar Y, Mir JN, u.\u202fa. The burden of hyperkalaemia in chronic kidney disease: a\u00a0systematic literature review. Clin Kidney J. 2025;18:sfaf127. https:\/\/doi.org\/10.1093\/ckj\/sfaf127","DOI":"10.1093\/ckj\/sfaf127"},{"key":"2708_CR35","doi-asserted-by":"publisher","unstructured":"Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, u.\u202fa. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a\u00a0randomised, double-blind, crossover trial. Lancet Lond Engl. 2015;386:2059\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(15)00257-3","DOI":"10.1016\/S0140-6736(15)00257-3"},{"key":"2708_CR36","doi-asserted-by":"publisher","unstructured":"Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, u.\u202fa. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892\u2013903. https:\/\/doi.org\/10.1056\/NEJMoa1303154","DOI":"10.1056\/NEJMoa1303154"},{"key":"2708_CR37","doi-asserted-by":"publisher","unstructured":"Freeman MW, Halvorsen Y\u2011D, Marshall W, Pater M, Isaacsohn J, Pearce C, u.\u202fa. Phase\u00a02 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med. 2023;388:395\u2013405. https:\/\/doi.org\/10.1056\/NEJMoa2213169","DOI":"10.1056\/NEJMoa2213169"},{"key":"2708_CR38","doi-asserted-by":"publisher","unstructured":"Massicotte-Azarniouch D, Canney M, Sood MM, Hundemer GL. Managing Hyperkalemia in the Modern Era: A\u00a0Case-Based Approach. Kidney Int Rep. 2023;8:1290\u2013300. https:\/\/doi.org\/10.1016\/j.ekir.2023.04.016","DOI":"10.1016\/j.ekir.2023.04.016"},{"key":"2708_CR39","doi-asserted-by":"publisher","unstructured":"Desai AS, Vaduganathan M, Claggett BL, Kulac IJ, Jhund PS, Cunningham J, u.\u202fa. Finerenone in Patients With a\u00a0Recent Worsening Heart Failure Event: The FINEARTS-HF Trial. J\u00a0Am Coll Cardiol. 2025;85:106\u201316. https:\/\/doi.org\/10.1016\/j.jacc.2024.09.004","DOI":"10.1016\/j.jacc.2024.09.004"},{"key":"2708_CR40","doi-asserted-by":"publisher","unstructured":"Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, Cherney D, Cronin L, u.\u202fa. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a\u00a0randomised, controlled, phase\u00a02\u00a0trial. Lancet. 2024;403:379\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(23)02408-X","DOI":"10.1016\/S0140-6736(23)02408-X"},{"key":"2708_CR41","doi-asserted-by":"publisher","unstructured":"Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a\u00a0randomized controlled trial. J\u00a0Am Coll Cardiol. 2009;54:505\u201312. https:\/\/doi.org\/10.1016\/j.jacc.2009.03.066","DOI":"10.1016\/j.jacc.2009.03.066"},{"key":"2708_CR42","doi-asserted-by":"publisher","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, u.\u202fa. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1313731","DOI":"10.1056\/NEJMoa1313731"},{"key":"2708_CR43","doi-asserted-by":"publisher","unstructured":"Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving H\u2011H, u.\u202fa. Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type\u00a02 diabetes and nephropathy. Diabetes Care. 2010;33:2304\u20139. https:\/\/doi.org\/10.2337\/dc10-0833","DOI":"10.2337\/dc10-0833"},{"key":"2708_CR44","doi-asserted-by":"publisher","unstructured":"Sarafidis P, Agarwal R, Pitt B, Wanner C, Filippatos G, Boletis J, u.\u202fa. Outcomes with Finerenone in Participants with Stage\u00a04\u00a0CKD and Type\u00a02 Diabetes: A\u00a0FIDELITY Subgroup Analysis. Clin J Am Soc Nephrol. 2023;18:602\u201312. https:\/\/doi.org\/10.2215\/CJN.0000000000000149","DOI":"10.2215\/CJN.0000000000000149"},{"key":"2708_CR45","doi-asserted-by":"publisher","unstructured":"Ravioli S, Pluess E, Funk G\u2011C, Walter P, Schwarz C, Exadaktylos AK, u.\u202fa. Dyskalemias in patients with acute kidney injury presenting to the emergency department are common and independent predictors of adverse outcome. Int J Clin Pract. 2021;75:e13653. https:\/\/doi.org\/10.1111\/ijcp.13653","DOI":"10.1111\/ijcp.13653"},{"key":"2708_CR46","doi-asserted-by":"publisher","unstructured":"Bachmann KF, Hess B, Koitm\u00e4e M, Bloch A, Regli A, Reintam Blaser A. Electrolyte disorders in the critically ill: a\u00a0retrospective analysis. Sci Rep. 2025;15:13943. https:\/\/doi.org\/10.1038\/s41598-025-98677-7","DOI":"10.1038\/s41598-025-98677-7"},{"key":"2708_CR47","doi-asserted-by":"publisher","unstructured":"Thomsen RW, Nicolaisen SK, Hasvold P, Sanchez RG, Pedersen L, Adelborg K, u.\u202fa. Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes\u2011a Danish population-based cohort study. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2018;33:1610\u201320. https:\/\/doi.org\/10.1093\/ndt\/gfx312","DOI":"10.1093\/ndt\/gfx312"},{"key":"2708_CR48","doi-asserted-by":"publisher","unstructured":"Lindner G, Pfortm\u00fcller CA, Leichtle AB, Fiedler GM, Exadaktylos AK. Age-related variety in electrolyte levels and prevalence of dysnatremias and dyskalemias in patients presenting to the emergency department. Gerontology. 2014;60:420\u20133. https:\/\/doi.org\/10.1159\/000360134","DOI":"10.1159\/000360134"},{"key":"2708_CR49","doi-asserted-by":"publisher","unstructured":"Valdivielso JM, Carriazo S, Martin M, Fernandez-Fernandez B, Bermudez-L\u00f3pez M, Ortiz A, u.\u202fa. Gender-specific risk factors and outcomes of hyperkalemia in CKD patients: smoking as a\u00a0driver of hyperkalemia in men. Clin Kidney J. 2024;17:sfad212. https:\/\/doi.org\/10.1093\/ckj\/sfad212","DOI":"10.1093\/ckj\/sfad212"},{"key":"2708_CR50","doi-asserted-by":"publisher","unstructured":"Hougen I, Leon SJ, Whitlock R, Rigatto C, Komenda P, Bohm C, u.\u202fa. Hyperkalemia and its Association With Mortality, Cardiovascular Events, Hospitalizations, and Intensive Care Unit Admissions in a\u00a0Population-Based Retrospective Cohort. Kidney Int Rep. 2021;6:1309\u201316. https:\/\/doi.org\/10.1016\/j.ekir.2021.02.038","DOI":"10.1016\/j.ekir.2021.02.038"},{"key":"2708_CR51","doi-asserted-by":"publisher","unstructured":"Pfortm\u00fcller CA, Leichtle AB, Fiedler GM, Exadaktylos AK, Lindner G. Hyperkalemia in the emergency department: etiology, symptoms and outcome of a\u00a0life threatening electrolyte disorder. Eur J Intern Med. 2013;24:e59-60. https:\/\/doi.org\/10.1016\/j.ejim.2013.02.010","DOI":"10.1016\/j.ejim.2013.02.010"},{"key":"2708_CR52","doi-asserted-by":"publisher","unstructured":"Sun J, Liu Q, Seery S, Sun L, Yuan Y, Wang W, u.\u202fa. The impact of hyperkalemia on ICU admission and mortality: a\u00a0retrospective study of Chinese emergency department data. BMC Emerg Med. 2024;24:95. https:\/\/doi.org\/10.1186\/s12873-024-01011-z","DOI":"10.1186\/s12873-024-01011-z"},{"key":"2708_CR53","doi-asserted-by":"publisher","unstructured":"Reinhardt M, Behnes M, Weidner K, Ayasse N, Lau F, Schmitt A, u.\u202fa. Potassium levels and short-term outcomes in heart failure with mildly reduced ejection fraction. Int J Cardiol. 2025;421:132878. https:\/\/doi.org\/10.1016\/j.ijcard.2024.132878","DOI":"10.1016\/j.ijcard.2024.132878"},{"key":"2708_CR54","doi-asserted-by":"publisher","unstructured":"Collins AJ, Pitt B, Reaven N, Funk S, McGaughey K, Wilson D, u.\u202fa. Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and\/or Diabetes. Am J Nephrol. 2017;46:213\u201321. https:\/\/doi.org\/10.1159\/000479802","DOI":"10.1159\/000479802"},{"key":"2708_CR55","doi-asserted-by":"publisher","unstructured":"Agiro A, Mu F, Cook E, Greatsinger A, Chen J, Zhao A, u.\u202fa. Hyperkalemia and the Risks of Adverse Cardiovascular Outcomes in Patients With Chronic Kidney Disease. J\u00a0Am Heart Assoc. 2025;14:e035256. https:\/\/doi.org\/10.1161\/JAHA.124.035256","DOI":"10.1161\/JAHA.124.035256"},{"key":"2708_CR56","doi-asserted-by":"publisher","unstructured":"de Rooij ENM, de Fijter JW, Le Cessie S, Hoorn EJ, Jager KJ, Chesnaye NC, u.\u202fa. Serum Potassium and Risk of Death or Kidney Replacement Therapy in Older People With CKD Stages 4\u20115: Eight-Year Follow-up. Am J Kidney Dis Off J Natl Kidney Found. 2023;82:257\u2013266.e1. https:\/\/doi.org\/10.1053\/j.ajkd.2023.03.008","DOI":"10.1053\/j.ajkd.2023.03.008"},{"key":"2708_CR57","doi-asserted-by":"publisher","unstructured":"Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, u.\u202fa. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009;169:1156\u201362. https:\/\/doi.org\/10.1001\/archinternmed.2009.132","DOI":"10.1001\/archinternmed.2009.132"},{"key":"2708_CR58","doi-asserted-by":"publisher","unstructured":"Gasparini A, Evans M, Barany P, Xu H, Jernberg T, \u00c4rnl\u00f6v J, u.\u202fa. Plasma potassium ranges associated with mortality across stages of chronic kidney disease: the Stockholm CREAtinine Measurements (SCREAM) project. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2019;34:1534\u201341. https:\/\/doi.org\/10.1093\/ndt\/gfy249","DOI":"10.1093\/ndt\/gfy249"},{"key":"2708_CR59","doi-asserted-by":"publisher","unstructured":"Kovesdy CP, Regidor DL, Mehrotra R, Jing J, McAllister CJ, Greenland S, u.\u202fa. Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin J Am Soc Nephrol CJASN. 2007;2:999\u20131007. https:\/\/doi.org\/10.2215\/CJN.04451206","DOI":"10.2215\/CJN.04451206"},{"key":"2708_CR60","doi-asserted-by":"publisher","unstructured":"Karaboyas A, Zee J, Brunelli SM, Usvyat LA, Weiner DE, Maddux FW, u.\u202fa. Dialysate Potassium, Serum Potassium, Mortality, and Arrhythmia Events in Hemodialysis: Results From the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis Off J Natl Kidney Found. 2017;69:266\u201377. https:\/\/doi.org\/10.1053\/j.ajkd.2016.09.015","DOI":"10.1053\/j.ajkd.2016.09.015"},{"key":"2708_CR61","doi-asserted-by":"publisher","unstructured":"Ferraro PM, Bolignano D, Aucella F, Brunori G, Gesualdo L, Limido A, u.\u202fa. Hyperkalemia excursions and risk of mortality and hospitalizations in hemodialysis patients: results from DOPPS-Italy. J\u00a0Nephrol. 2022;35:707\u20139. https:\/\/doi.org\/10.1007\/s40620-021-01209-5","DOI":"10.1007\/s40620-021-01209-5"},{"key":"2708_CR62","doi-asserted-by":"publisher","unstructured":"Bakris G, Agiro A, Mu F, Cook EE, Greatsinger A, Sundar M, u.\u202fa. Consequences of Recurrent Hyperkalemia on Cardiovascular Outcomes and Mortality. JACC Adv. 2024;3:101331. https:\/\/doi.org\/10.1016\/j.jacadv.2024.101331","DOI":"10.1016\/j.jacadv.2024.101331"},{"key":"2708_CR63","doi-asserted-by":"publisher","unstructured":"Trevisan M, Clase CM, Evans M, Popov T, Ludvigsson JF, Sj\u00f6lander A, u.\u202fa. Patterns of chronic and transient hyperkalaemia and clinically important outcomes in patients with chronic kidney disease. Clin Kidney J. 2022;15:153\u201361. https:\/\/doi.org\/10.1093\/ckj\/sfab159","DOI":"10.1093\/ckj\/sfab159"},{"key":"2708_CR64","doi-asserted-by":"publisher","unstructured":"Gorriz JL, D\u2019Marco L, Pastor-Gonz\u00e1lez A, Molina P, Gonzalez-Rico M, Puchades MJ, u.\u202fa. Long-term mortality and trajectory of potassium measurements following an episode of acute severe hyperkalaemia. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2022;37:522\u201330. https:\/\/doi.org\/10.1093\/ndt\/gfab003","DOI":"10.1093\/ndt\/gfab003"},{"key":"2708_CR65","doi-asserted-by":"publisher","unstructured":"Preston RA, Afshartous D, Rodco R, Alonso AB, Garg D. Evidence for a\u00a0gastrointestinal-renal kaliuretic signaling axis in humans. Kidney Int. 2015;88:1383\u201391. https:\/\/doi.org\/10.1038\/ki.2015.243","DOI":"10.1038\/ki.2015.243"},{"key":"2708_CR66","doi-asserted-by":"publisher","unstructured":"Agarwal R, Afzalpurkar R, Fordtran JS. Pathophysiology of potassium absorption and secretion by the human intestine. Gastroenterology. 1994;107:548\u201371. https:\/\/doi.org\/10.1016\/0016-5085(94)90184-8","DOI":"10.1016\/0016-5085(94)90184-8"},{"key":"2708_CR67","doi-asserted-by":"publisher","unstructured":"Ceccanti C, Guidi L, D\u2019Alessandro C, Cupisti A. Potassium Bioaccessibility in Uncooked and Cooked Plant Foods: Results from a\u00a0Static In Vitro Digestion Methodology. Toxins. 2022;14:668. https:\/\/doi.org\/10.3390\/toxins14100668","DOI":"10.3390\/toxins14100668"},{"key":"2708_CR68","doi-asserted-by":"publisher","unstructured":"DeFronzo RA, Felig P, Ferrannini E, Wahren J. Effect of graded doses of insulin on splanchnic and peripheral potassium metabolism in man. Am J Physiol. 1980;238:E421-427. https:\/\/doi.org\/10.1152\/ajpendo.1980.238.5.E421","DOI":"10.1152\/ajpendo.1980.238.5.E421"},{"key":"2708_CR69","doi-asserted-by":"publisher","unstructured":"Wouda RD, Gritter M, Karsten M, Michels EHA, Nieuweboer TM, Danser AHJ, u.\u202fa. Kaliuresis and Intracellular Uptake of Potassium with Potassium Citrate and Potassium Chloride Supplements: A\u00a0Randomized Controlled Trial. Clin J Am Soc Nephrol CJASN. 2023;18:1260\u201371. https:\/\/doi.org\/10.2215\/CJN.0000000000000228","DOI":"10.2215\/CJN.0000000000000228"},{"key":"2708_CR70","doi-asserted-by":"publisher","unstructured":"Rabelink TJ, Koomans HA, Hen\u00e9 RJ, Dorhout Mees EJ. Early and late adjustment to potassium loading in humans. Kidney Int. 1990;38:942\u20137. https:\/\/doi.org\/10.1038\/ki.1990.295","DOI":"10.1038\/ki.1990.295"},{"key":"2708_CR71","doi-asserted-by":"publisher","unstructured":"Unwin RJ, Luft FC, Shirley DG. Pathophysiology and management of hypokalemia: a\u00a0clinical perspective. Nat Rev Nephrol. 2011;7:75\u201384. https:\/\/doi.org\/10.1038\/nrneph.2010.175","DOI":"10.1038\/nrneph.2010.175"},{"key":"2708_CR72","doi-asserted-by":"publisher","unstructured":"Epstein M, Lifschitz MD. The Unappreciated Role of Extrarenal and Gut Sensors in Modulating Renal Potassium Handling: Implications for Diagnosis of Dyskalemias and Interpreting Clinical Trials. Kidney Int Rep. 2016;1:43\u201356. https:\/\/doi.org\/10.1016\/j.ekir.2016.03.001","DOI":"10.1016\/j.ekir.2016.03.001"},{"key":"2708_CR73","doi-asserted-by":"publisher","unstructured":"Grimm PR, Tatomir A, Rosenbaek LL, Kim BY, Li D, Delpire EJ, u.\u202fa. Dietary potassium stimulates Ppp1Ca-Ppp1r1a dephosphorylation of kidney NaCl cotransporter and reduces blood pressure. J\u00a0Clin Invest. 2023;133:e158498. https:\/\/doi.org\/10.1172\/JCI158498","DOI":"10.1172\/JCI158498"},{"key":"2708_CR74","doi-asserted-by":"publisher","unstructured":"Palmer BF, Clegg DJ. Physiology and Pathophysiology of Potassium Homeostasis: Core Curriculum 2019. Am J Kidney Dis Off J Natl Kidney Found. 2019;74:682\u201395. https:\/\/doi.org\/10.1053\/j.ajkd.2019.03.427","DOI":"10.1053\/j.ajkd.2019.03.427"},{"key":"2708_CR75","doi-asserted-by":"publisher","unstructured":"Welling PA. Regulation of renal potassium secretion: molecular mechanisms. Semin Nephrol. 2013;33:215\u201328. https:\/\/doi.org\/10.1016\/j.semnephrol.2013.04.002","DOI":"10.1016\/j.semnephrol.2013.04.002"},{"key":"2708_CR76","doi-asserted-by":"publisher","unstructured":"Al-Qusairi L, Ferdaus MZ, Pham TD, Li D, Grimm PR, Zapf AM, u.\u202fa. Dietary anions control potassium excretion: it is more than a\u00a0poorly absorbable anion effect. Am J Physiol Renal Physiol. 2023;325:F377\u201393. https:\/\/doi.org\/10.1152\/ajprenal.00193.2023","DOI":"10.1152\/ajprenal.00193.2023"},{"key":"2708_CR77","doi-asserted-by":"publisher","unstructured":"Himathongkam T, Dluhy RG, Williams GH. Potassim-aldosterone-renin interrelationships. J\u00a0Clin Endocrinol Metab. 1975;41:153\u20139. https:\/\/doi.org\/10.1210\/jcem-41-1-153","DOI":"10.1210\/jcem-41-1-153"},{"key":"2708_CR78","doi-asserted-by":"publisher","unstructured":"Field MJ, Stanton BA, Giebisch GH. Influence of ADH on renal potassium handling: a\u00a0micropuncture and microperfusion study. Kidney Int. 1984;25:502\u201311. https:\/\/doi.org\/10.1038\/ki.1984.46","DOI":"10.1038\/ki.1984.46"},{"key":"2708_CR79","doi-asserted-by":"publisher","unstructured":"Harris AN, Grimm PR, Lee H\u2011W, Delpire E, Fang L, Verlander JW, u.\u202fa. Mechanism of Hyperkalemia-Induced Metabolic Acidosis. J\u00a0Am Soc Nephrol JASN. 2018;29:1411\u201325. https:\/\/doi.org\/10.1681\/ASN.2017111163","DOI":"10.1681\/ASN.2017111163"},{"key":"2708_CR80","doi-asserted-by":"publisher","unstructured":"Palmer BF, Clegg DJ. Extrarenal Effects of Aldosterone on Potassium Homeostasis. Kidney360. 2022;3:561\u20138. https:\/\/doi.org\/10.34067\/KID.0006762021","DOI":"10.34067\/KID.0006762021"},{"key":"2708_CR81","doi-asserted-by":"publisher","unstructured":"Choi HY, Ha SK. Potassium balances in maintenance hemodialysis. Electrolyte Blood Press E BP. 2013;11:9\u201316. https:\/\/doi.org\/10.5049\/EBP.2013.11.1.9","DOI":"10.5049\/EBP.2013.11.1.9"},{"key":"2708_CR82","doi-asserted-by":"publisher","unstructured":"Evers S, Engelien A, Karsch V, Hund M.\u00a0Secondary hyperkalaemic paralysis. J\u00a0Neurol Neurosurg Psychiatry. 1998;64:249\u201352. https:\/\/doi.org\/10.1136\/jnnp.64.2.249","DOI":"10.1136\/jnnp.64.2.249"},{"key":"2708_CR83","doi-asserted-by":"publisher","unstructured":"Kimmons LA, Usery JB. Acute ascending muscle weakness secondary to medication-induced hyperkalemia. Case Rep Med. 2014;2014:789529. https:\/\/doi.org\/10.1155\/2014\/789529","DOI":"10.1155\/2014\/789529"},{"key":"2708_CR84","doi-asserted-by":"publisher","unstructured":"Karmacharya P, Poudel DR, Pathak R, Rettew A, Alweis R. Acute hyperkalemia leading to flaccid paralysis: a\u00a0review of hyperkalemic manifestations. J\u00a0Community Hosp Intern Med Perspect. 2015;5:27993. https:\/\/doi.org\/10.3402\/jchimp.v5.27993","DOI":"10.3402\/jchimp.v5.27993"},{"key":"2708_CR85","doi-asserted-by":"publisher","unstructured":"Robert T, Mesnard L. How hyperkalemia affects the heart: clinical implications. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2025;40:1063\u20135. https:\/\/doi.org\/10.1093\/ndt\/gfae287","DOI":"10.1093\/ndt\/gfae287"},{"key":"2708_CR86","doi-asserted-by":"publisher","unstructured":"Mattu A, Brady WJ, Robinson DA. Electrocardiographic manifestations of hyperkalemia. Am J Emerg Med. 2000;18:721\u20139. https:\/\/doi.org\/10.1053\/ajem.2000.7344","DOI":"10.1053\/ajem.2000.7344"},{"key":"2708_CR87","doi-asserted-by":"publisher","unstructured":"Palmer BF, Clegg DJ. Hyperkalemia treatment standard. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2024;39:1097\u2013104. https:\/\/doi.org\/10.1093\/ndt\/gfae056","DOI":"10.1093\/ndt\/gfae056"},{"key":"2708_CR88","unstructured":"Parham WA, Mehdirad AA, Biermann KM, Fredman CS. Hyperkalemia revisited. Tex Heart Inst J. 2006;33:40\u20137."},{"key":"2708_CR89","doi-asserted-by":"publisher","unstructured":"Littmann L, Gibbs MA. Electrocardiographic manifestations of severe hyperkalemia. J\u00a0Electrocardiol. 2018;51:814\u20137. https:\/\/doi.org\/10.1016\/j.jelectrocard.2018.06.018","DOI":"10.1016\/j.jelectrocard.2018.06.018"},{"key":"2708_CR90","doi-asserted-by":"publisher","unstructured":"Weiss JN, Qu Z, Shivkumar K. Electrophysiology of Hypokalemia and Hyperkalemia. Circ Arrhythm Electrophysiol. 2017;10:e004667. https:\/\/doi.org\/10.1161\/CIRCEP.116.004667","DOI":"10.1161\/CIRCEP.116.004667"},{"key":"2708_CR91","doi-asserted-by":"publisher","unstructured":"Ryuge A, Nomura A, Shimizu H, Fujita Y. Warning: The ECG May Be Normal in Severe Hyperkalemia. Intern Med Tokyo Jpn. 2017;56:2243\u20134. https:\/\/doi.org\/10.2169\/internalmedicine.6895-15","DOI":"10.2169\/internalmedicine.6895-15"},{"key":"2708_CR92","doi-asserted-by":"publisher","unstructured":"Varga C, K\u00e1lm\u00e1n Z, Szak\u00e1ll A, Drubits K, Koch M, B\u00e1nhegyi R, u.\u202fa. ECG alterations suggestive of hyperkalemia in normokalemic versus hyperkalemic patients. BMC Emerg Med. 2019;19:33. https:\/\/doi.org\/10.1186\/s12873-019-0247-0","DOI":"10.1186\/s12873-019-0247-0"},{"key":"2708_CR93","doi-asserted-by":"publisher","unstructured":"\u00dcnl\u00fc L, Stephan F\u2011P, Riede FN, Mettler AC, Dutilh G, Capoferri G, u.\u202fa. Diagnostic accuracy of emergency department ECGs in hyperkalemia detection: A\u00a0cross-sectional study. Eur J Intern Med. 2025;136:56\u201362. https:\/\/doi.org\/10.1016\/j.ejim.2025.03.038","DOI":"10.1016\/j.ejim.2025.03.038"},{"key":"2708_CR94","doi-asserted-by":"publisher","unstructured":"Montague BT, Ouellette JR, Buller GK. Retrospective review of the frequency of ECG changes in hyperkalemia. Clin J Am Soc Nephrol CJASN. 2008;3:324\u201330. https:\/\/doi.org\/10.2215\/CJN.04611007","DOI":"10.2215\/CJN.04611007"},{"key":"2708_CR95","doi-asserted-by":"publisher","unstructured":"Kim D, Jeong J, Kim J, Cho Y, Park I, Lee S\u2011M, u.\u202fa. Hyperkalemia Detection in Emergency Departments Using Initial ECGs: A\u00a0Smartphone AI ECG Analyzer vs. Board-Certified Physicians. J\u00a0Korean Med Sci. 2023;38:e322. https:\/\/doi.org\/10.3346\/jkms.2023.38.e322","DOI":"10.3346\/jkms.2023.38.e322"},{"key":"2708_CR96","doi-asserted-by":"publisher","unstructured":"Xu D, Zhou B, Zhang J, Li C, Guan C, Liu Y, u.\u202fa. Prediction of hyperkalemia in ESRD patients by identification of multiple leads and multiple features on ECG. Ren Fail. 2023;45:2212800. https:\/\/doi.org\/10.1080\/0886022X.2023.2212800","DOI":"10.1080\/0886022X.2023.2212800"},{"key":"2708_CR97","doi-asserted-by":"publisher","unstructured":"Pradhan J, Harding AM, Taylor SE, Lam Q. Implications of differences between point-of-care blood gas analyser and laboratory analyser potassium results on hyperkalaemia diagnosis & treatment. Intern Med J. 2023;53:2035\u201341. https:\/\/doi.org\/10.1111\/imj.16020","DOI":"10.1111\/imj.16020"},{"key":"2708_CR98","doi-asserted-by":"publisher","unstructured":"Ghumman GM, Baqi A, Adil ANK, Khatri V. Role of point-of-care arterial blood potassium in diagnosing pseudohyperkalemia. Proc Bayl Univ Med Cent. 2022;35:866\u20137. https:\/\/doi.org\/10.1080\/08998280.2022.2108979","DOI":"10.1080\/08998280.2022.2108979"},{"key":"2708_CR99","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105:S117\u2013314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"2708_CR100","doi-asserted-by":"publisher","unstructured":"Huth EJ, Squires RD, Elkinton JR. EXPERIMENTAL POTASSIUM DEPLETION IN NORMAL HUMAN SUBJECTS. II. RENAL AND HORMONAL FACTORS IN THE DEVELOPMENT OF EXTRACELLULAR ALKALOSIS DURING DEPLETION. J\u00a0Clin Invest. American Society for Clinical Investigation; 1959;38:1149\u201365. https:\/\/doi.org\/10.1172\/JCI103891","DOI":"10.1172\/JCI103891"},{"key":"2708_CR101","doi-asserted-by":"publisher","unstructured":"Halperin ML. Assessing the renal response in patients with potassium disorders: a\u00a0shift in emphasis from the TTKG to the urine K+\/creatinine ratio. Afr J Nephrol. 2017;20:22\u20134. https:\/\/doi.org\/10.21804\/20-1-2453","DOI":"10.21804\/20-1-2453"},{"key":"2708_CR102","unstructured":"Hollander-Rodriguez JC, Calvert JF. Hyperkalemia. Am Fam Physician. 2006;73:283\u201390."},{"key":"2708_CR103","doi-asserted-by":"publisher","unstructured":"Dluhy RG, Axelrod L, Underwood RH, Williams GH. Studies of the control of plasma aldosterone concentration in normal man. II. Effect of dietary potassium and acute potassium infusion. J\u00a0Clin Invest. 1972;51:1950\u20137. https:\/\/doi.org\/10.1172\/JCI107001","DOI":"10.1172\/JCI107001"},{"key":"2708_CR104","doi-asserted-by":"publisher","unstructured":"Ruiz-S\u00e1nchez JG, Calle-Pascual AL, Rubio-Herrera M\u00c1, De Miguel Novoa MP, G\u00f3mez-Hoyos E, Runkle I. Clinical manifestations and associated factors in acquired hypoaldosteronism in endocrinological practice. Front Endocrinol. 2022;13:990148. https:\/\/doi.org\/10.3389\/fendo.2022.990148","DOI":"10.3389\/fendo.2022.990148"},{"key":"2708_CR105","doi-asserted-by":"publisher","unstructured":"Arruda JA, Batlle DC, Sehy JT, Roseman MK, Baronowski RL, Kurtzman NA. Hyperkalemia and renal insufficiency: role of selective aldosterone deficiency and tubular unresponsiveness to aldosterone. Am J Nephrol. 1981;1:160\u20137. https:\/\/doi.org\/10.1159\/000166533","DOI":"10.1159\/000166533"},{"key":"2708_CR106","doi-asserted-by":"publisher","unstructured":"Takieddine LT, El-Khoury JM. Laboratory Anomalies in the Basic Metabolic Panel: Core Curriculum 2025. Am J Kidney Dis Off J Natl Kidney Found. 2025;85:104\u201314. https:\/\/doi.org\/10.1053\/j.ajkd.2024.06.019","DOI":"10.1053\/j.ajkd.2024.06.019"},{"key":"2708_CR107","doi-asserted-by":"publisher","unstructured":"Lano G, Lefevre F, Buffat C, Schlegel L, Dho E, Jantzen R, u.\u202fa. Pseudo-hyperkalaemia in ambulatory samples: the never-ending story? Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2022;37:991\u20133. https:\/\/doi.org\/10.1093\/ndt\/gfab355","DOI":"10.1093\/ndt\/gfab355"},{"key":"2708_CR108","doi-asserted-by":"publisher","unstructured":"Saleh-Anaraki K, Jain A, Wilcox CS, Pourafshar N. Pseudohyperkalemia: Three Cases and a\u00a0Review of Literature. Am J Med. 2022;135:e150\u20134. https:\/\/doi.org\/10.1016\/j.amjmed.2022.01.036","DOI":"10.1016\/j.amjmed.2022.01.036"},{"key":"2708_CR109","doi-asserted-by":"publisher","unstructured":"Arani N, Wechsler AH. Hyperkalemia in the setting of severe leukocytosis: Should you treat? Am J Emerg Med. 2023;66:174.e1-174.e2. https:\/\/doi.org\/10.1016\/j.ajem.2023.01.008","DOI":"10.1016\/j.ajem.2023.01.008"},{"key":"2708_CR110","doi-asserted-by":"publisher","unstructured":"Kalan U, Vardi J, Kaya SK, Gunes AK. A\u00a0rare case of essential thrombocythemia with pseudo-hyperkalemia. Blood Coagul Fibrinolysis Int J Haemost Thromb. 2024;35:214\u20136. https:\/\/doi.org\/10.1097\/MBC.0000000000001295","DOI":"10.1097\/MBC.0000000000001295"},{"key":"2708_CR111","doi-asserted-by":"publisher","unstructured":"Fujimaru T, Hirose K, Yazawa M, Nagahama M, Kovesdy CP, Electrolyte Winter Seminar Collaborative Group. Pathophysiology and causes of hyperkalemia: unraveling causes beyond kidney dysfunction. Clin Exp Nephrol. 2025; https:\/\/doi.org\/10.1007\/s10157-025-02711-x","DOI":"10.1007\/s10157-025-02711-x"},{"key":"2708_CR112","doi-asserted-by":"publisher","unstructured":"Kuwano K, Shimizu S, Fujita Y, Akatsu S, Shibagaki Y, Yazawa M. Marked hyperkalemia due to inappropriate blood sample storage in two suspected cases of familial pseudohyperkalemia. CEN Case Rep. 2023;12:397\u2013401. https:\/\/doi.org\/10.1007\/s13730-023-00781-y","DOI":"10.1007\/s13730-023-00781-y"},{"key":"2708_CR113","doi-asserted-by":"publisher","unstructured":"Sennels HP, J\u00f8rgensen HL, Goetze JP, Fahrenkrug J. Rhythmic 24-hour variations of frequently used clinical biochemical parameters in healthy young males--the Bispebjerg study of diurnal variations. Scand J Clin Lab Invest. 2012;72:287\u201395. https:\/\/doi.org\/10.3109\/00365513.2012.662281","DOI":"10.3109\/00365513.2012.662281"},{"key":"2708_CR114","doi-asserted-by":"publisher","unstructured":"Schmidt ST, Ditting T, Deutsch B, Schutte R, Friedrich S, Kistner I, u.\u202fa. Circadian rhythm and day to day variability of serum potassium concentration: a\u00a0pilot study. J\u00a0Nephrol. 2015;28:165\u201372. https:\/\/doi.org\/10.1007\/s40620-014-0115-7","DOI":"10.1007\/s40620-014-0115-7"},{"key":"2708_CR115","doi-asserted-by":"publisher","unstructured":"St-Jules DE, Clegg DJ, Palmer BF, Carrero J\u2011J. Can Novel Potassium Binders Liberate People with Chronic Kidney Disease from the Low-Potassium Diet? A\u00a0Cautionary Tale. Clin J Am Soc Nephrol CJASN. 2022;17:467\u201372. https:\/\/doi.org\/10.2215\/CJN.09660721","DOI":"10.2215\/CJN.09660721"},{"key":"2708_CR116","doi-asserted-by":"publisher","unstructured":"Aronson PS, Giebisch G. Effects of pH on potassium: new explanations for old observations. J\u00a0Am Soc Nephrol JASN. 2011;22:1981\u20139. https:\/\/doi.org\/10.1681\/ASN.2011040414","DOI":"10.1681\/ASN.2011040414"},{"key":"2708_CR117","doi-asserted-by":"publisher","unstructured":"Aronson PS, Giebisch G. Effects of pH on potassium: new explanations for old observations. J\u00a0Am Soc Nephrol JASN. 2011;22:1981\u20139. https:\/\/doi.org\/10.1681\/ASN.2011040414","DOI":"10.1681\/ASN.2011040414"},{"key":"2708_CR118","doi-asserted-by":"publisher","unstructured":"Sirken G, Raja R, Garces J, Bloom E, Fumo P. Contrast-induced translocational hyponatremia and hyperkalemia in advanced kidney disease. Am J Kidney Dis Off J Natl Kidney Found. 2004;43:e31-35. https:\/\/doi.org\/10.1053\/j.ajkd.2003.10.028","DOI":"10.1053\/j.ajkd.2003.10.028"},{"key":"2708_CR119","doi-asserted-by":"publisher","unstructured":"Jurkat-Rott K, Lehmann-Horn F. Genotype-phenotype correlation and therapeutic rationale in hyperkalemic periodic paralysis. Neurother J Am Soc Exp Neurother. 2007;4:216\u201324. https:\/\/doi.org\/10.1016\/j.nurt.2007.02.001","DOI":"10.1016\/j.nurt.2007.02.001"},{"key":"2708_CR120","doi-asserted-by":"publisher","unstructured":"Karet FE. Mechanisms in hyperkalemic renal tubular acidosis. J\u00a0Am Soc Nephrol JASN. 2009;20:251\u20134. https:\/\/doi.org\/10.1681\/ASN.2008020166","DOI":"10.1681\/ASN.2008020166"},{"key":"2708_CR121","doi-asserted-by":"publisher","unstructured":"Adachi M, Motegi S, Nagahara K, Ochi A, Toyoda J, Mizuno K. Classification of pseudohypoaldosteronism type\u00a0II as type\u00a0IV renal tubular acidosis: results of a\u00a0literature review. Endocr J. 2023;70:723\u20139. https:\/\/doi.org\/10.1507\/endocrj.EJ22-0607","DOI":"10.1507\/endocrj.EJ22-0607"},{"key":"2708_CR122","doi-asserted-by":"publisher","unstructured":"Batlle DC, Arruda JA, Kurtzman NA. Hyperkalemic distal renal tubular acidosis associated with obstructive uropathy. N Engl J Med. 1981;304:373\u201380. https:\/\/doi.org\/10.1056\/NEJM198102123040701","DOI":"10.1056\/NEJM198102123040701"},{"key":"2708_CR123","doi-asserted-by":"publisher","unstructured":"Ravioli S, Woitok BK, Lindner G. BRASH syndrome - fact or fiction? A\u00a0first analysis of the prevalence and relevance of a\u00a0newly described syndrome. Eur J Emerg Med Off J Eur Soc Emerg Med. 2021;28:153\u20135. https:\/\/doi.org\/10.1097\/MEJ.0000000000000762","DOI":"10.1097\/MEJ.0000000000000762"},{"key":"2708_CR124","doi-asserted-by":"publisher","unstructured":"Yang M, White PC. Genetics and Pathophysiology of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. J\u00a0Clin Endocrinol Metab. 2025;110:S1\u201312. https:\/\/doi.org\/10.1210\/clinem\/dgae535","DOI":"10.1210\/clinem\/dgae535"},{"key":"2708_CR125","doi-asserted-by":"publisher","unstructured":"Ruiz-S\u00e1nchez JG, Calle-Pascual AL, Rubio-Herrera M\u00c1, De Miguel Novoa MP, G\u00f3mez-Hoyos E, Runkle I. Isolated hypoaldosteronism is a\u00a0cause of hypovolemic but not euvolemic hyponatremia. Endocr Connect. 2024;13:e230430. https:\/\/doi.org\/10.1530\/EC-23-0430","DOI":"10.1530\/EC-23-0430"},{"key":"2708_CR126","doi-asserted-by":"publisher","unstructured":"Nethathe GD, Lipman J, Anderson R, Feldman C. CIRMI\u2011a new term for a\u00a0concept worthy of further exploration: a\u00a0narrative review. Ann Transl Med. 2022;10:646. https:\/\/doi.org\/10.21037\/atm-21-5572","DOI":"10.21037\/atm-21-5572"},{"key":"2708_CR127","doi-asserted-by":"publisher","unstructured":"Oster JR, Singer I, Fishman LM. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med. 1995;98:575\u201386. https:\/\/doi.org\/10.1016\/s0002-9343(99)80017-5","DOI":"10.1016\/s0002-9343(99)80017-5"},{"key":"2708_CR128","doi-asserted-by":"publisher","unstructured":"Laffin LJ, Rodman D, Luther JM, Vaidya A, Weir MR, Rajicic N, u.\u202fa. Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension: The Target-HTN Randomized Clinical Trial. JAMA. 2023;330:1140\u201350. https:\/\/doi.org\/10.1001\/jama.2023.16029","DOI":"10.1001\/jama.2023.16029"},{"key":"2708_CR129","doi-asserted-by":"publisher","unstructured":"Gupta N, Prasad P. Hyperkalemia in diabetes: newer insights into mechanism and treatment. Postgrad Med J. 2022;98:e45. https:\/\/doi.org\/10.1136\/postgradmedj-2021-140226","DOI":"10.1136\/postgradmedj-2021-140226"},{"key":"2708_CR130","doi-asserted-by":"publisher","unstructured":"Hoorn EJ, Nelson JH, McCormick JA, Ellison DH. The WNK Kinase Network Regulating Sodium, Potassium, and Blood Pressure. J\u00a0Am Soc Nephrol. 2011;22:605. https:\/\/doi.org\/10.1681\/ASN.2010080827","DOI":"10.1681\/ASN.2010080827"},{"key":"2708_CR131","doi-asserted-by":"publisher","unstructured":"Gordon RD, Geddes RA, Pawsey CG, O\u2019Halloran MW. Hypertension and severe hyperkalaemia associated with suppression of renin and aldosterone and completely reversed by dietary sodium restriction. Australas Ann Med. 1970;19:287\u201394. https:\/\/doi.org\/10.1111\/imj.1970.19.4.287","DOI":"10.1111\/imj.1970.19.4.287"},{"key":"2708_CR132","doi-asserted-by":"publisher","unstructured":"O\u2019Shaughnessy KM. Gordon Syndrome: a\u00a0continuing story. Pediatr Nephrol Berl Ger. 2015;30:1903\u20138. https:\/\/doi.org\/10.1007\/s00467-014-2956-7","DOI":"10.1007\/s00467-014-2956-7"},{"key":"2708_CR133","doi-asserted-by":"publisher","unstructured":"Hoorn EJ, Walsh SB, McCormick JA, F\u00fcrstenberg A, Yang C\u2011L, Roeschel T, u.\u202fa. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med. 2011;17:1304\u20139. https:\/\/doi.org\/10.1038\/nm.2497","DOI":"10.1038\/nm.2497"},{"key":"2708_CR134","doi-asserted-by":"publisher","unstructured":"Duan X\u2011P, Zhang C\u2011B, Wang W\u2011H, Lin D\u2011H. Role of calcineurin in regulating renal potassium (K+) excretion: Mechanisms of calcineurin inhibitor-induced hyperkalemia. Acta Physiol Oxf Engl. 2024;240:e14189. https:\/\/doi.org\/10.1111\/apha.14189","DOI":"10.1111\/apha.14189"},{"key":"2708_CR135","doi-asserted-by":"publisher","unstructured":"Rizk JG, Lazo JG, Quan D, Gabardi S, Rizk Y, Streja E, u.\u202fa. Mechanisms and management of drug-induced hyperkalemia in kidney transplant patients. Rev Endocr Metab Disord. 2021;22:1157\u201370. https:\/\/doi.org\/10.1007\/s11154-021-09677-7","DOI":"10.1007\/s11154-021-09677-7"},{"key":"2708_CR136","doi-asserted-by":"publisher","unstructured":"Smyrli M, Sarafidis PA, Loutradis C, Korogiannou M, Boletis IN, Marinaki S. Prevalence and factors associated with hyperkalaemia in stable kidney transplant recipients. Clin Kidney J. 2022;15:43\u201350. https:\/\/doi.org\/10.1093\/ckj\/sfab129","DOI":"10.1093\/ckj\/sfab129"},{"key":"2708_CR137","doi-asserted-by":"publisher","unstructured":"Adelborg K, Nicolaisen SK, Hasvold P, Palaka E, Pedersen L, Thomsen RW. Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients \u2014 A population-based cohort study. PLOS ONE. Public Library of Science; 2019;14:e0218739. https:\/\/doi.org\/10.1371\/journal.pone.0218739","DOI":"10.1371\/journal.pone.0218739"},{"key":"2708_CR138","doi-asserted-by":"publisher","unstructured":"van Boemmel-Wegmann S, Bauer C, Schuchhardt J, Hartenstein A, James G, Pessina E, u.\u202fa. Hyperkalemia Incidence in Patients With Non-Dialysis Chronic Kidney Disease: A\u00a0Large Retrospective Cohort Study From United States Clinical Care. Kidney Med. 2024;6:100879. https:\/\/doi.org\/10.1016\/j.xkme.2024.100879","DOI":"10.1016\/j.xkme.2024.100879"},{"key":"2708_CR139","doi-asserted-by":"publisher","unstructured":"Kreitzer N, Albert NM, Amin AN, Beavers CJ, Becker RC, Fonarow G, u.\u202fa. EMCREG-International Multidisciplinary Consensus Panel on Management of Hyperkalemia in Chronic Kidney Disease and Heart Failure. Cardiorenal Med. 2025;15:133\u201352. https:\/\/doi.org\/10.1159\/000543385","DOI":"10.1159\/000543385"},{"key":"2708_CR140","doi-asserted-by":"publisher","unstructured":"Agiro A, Duling I, Eudicone J, Davis J, Brahmbhatt YG, Cooper K. The prevalence of predialysis hyperkalemia and associated characteristics among hemodialysis patients: The RE-UTILIZE study. Hemodial Int Int Symp Home Hemodial. 2022;26:397\u2013407. https:\/\/doi.org\/10.1111\/hdi.13006","DOI":"10.1111\/hdi.13006"},{"key":"2708_CR141","doi-asserted-by":"publisher","unstructured":"Yusuf AA, Hu Y, Singh B, Menoyo JA, Wetmore JB. Serum Potassium Levels and Mortality in Hemodialysis Patients: A\u00a0Retrospective Cohort Study. Am J Nephrol. 2016;44:179\u201386. https:\/\/doi.org\/10.1159\/000448341","DOI":"10.1159\/000448341"},{"key":"2708_CR142","doi-asserted-by":"publisher","unstructured":"Bleyer AJ, Hartman J, Brannon PC, Reeves-Daniel A, Satko SG, Russell G. Characteristics of sudden death in hemodialysis patients. Kidney Int. 2006;69:2268\u201373. https:\/\/doi.org\/10.1038\/sj.ki.5000446","DOI":"10.1038\/sj.ki.5000446"},{"key":"2708_CR143","doi-asserted-by":"publisher","unstructured":"Allon M, Takeshian A, Shanklin N. Effect of insulin-plus-glucose infusion with or without epinephrine on fasting hyperkalemia. Kidney Int. 1993;43:212\u20137. https:\/\/doi.org\/10.1038\/ki.1993.34","DOI":"10.1038\/ki.1993.34"},{"key":"2708_CR144","doi-asserted-by":"publisher","unstructured":"Sumida K, Biruete A, Kistler BM, Khor B\u2011H, Ebrahim Z, Giannini R, u.\u202fa. New Insights Into Dietary Approaches to Potassium Management in Chronic Kidney Disease. J\u00a0Ren Nutr Off J Counc Ren Nutr Natl Kidney Found. 2023;33:S6\u201312. https:\/\/doi.org\/10.1053\/j.jrn.2022.12.003","DOI":"10.1053\/j.jrn.2022.12.003"},{"key":"2708_CR145","doi-asserted-by":"publisher","unstructured":"Bansal S, Pergola PE. Current Management of Hyperkalemia in Patients on Dialysis. Kidney Int Rep. 2020;5:779\u201389. https:\/\/doi.org\/10.1016\/j.ekir.2020.02.1028","DOI":"10.1016\/j.ekir.2020.02.1028"},{"key":"2708_CR146","doi-asserted-by":"publisher","unstructured":"Walsh M, Collister D, Gallagher M, Mark PB, de Zoysa JR, Tyrwhitt J, u.\u202fa. Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial. Lancet Lond Engl. 2025;406:695\u2013704. https:\/\/doi.org\/10.1016\/S0140-6736(25)01198-5","DOI":"10.1016\/S0140-6736(25)01198-5"},{"key":"2708_CR147","doi-asserted-by":"publisher","unstructured":"Walsh M, Manns B, Garg AX, Bueti J, Rabbat C, Smyth A, u.\u202fa. The Safety of Eplerenone in Hemodialysis Patients: A\u00a0Noninferiority Randomized Controlled Trial. Clin J Am Soc Nephrol CJASN. 2015;10:1602\u20138. https:\/\/doi.org\/10.2215\/CJN.12371214","DOI":"10.2215\/CJN.12371214"},{"key":"2708_CR148","doi-asserted-by":"publisher","unstructured":"Sumida K, Yamagata K, Kovesdy CP. Constipation in CKD. Kidney Int Rep. 2020;5:121\u201334. https:\/\/doi.org\/10.1016\/j.ekir.2019.11.002","DOI":"10.1016\/j.ekir.2019.11.002"},{"key":"2708_CR149","doi-asserted-by":"publisher","unstructured":"Giannese D, D\u2019Alessandro C, Pellegrino N, Panichi V, Cupisti A. RAASi Therapy Attenuates the Association between 24\u2011h Urinary Potassium Excretion and Dietary Potassium Intake in CKD Patients. Nutrients. 2023;15:2454. https:\/\/doi.org\/10.3390\/nu15112454","DOI":"10.3390\/nu15112454"},{"key":"2708_CR150","doi-asserted-by":"publisher","unstructured":"Roush GC, Ernst ME, Kostis JB, Yeasmin S, Sica DA. Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium: systematic review and meta-analyses. J\u00a0Hypertens. 2016;34:11\u20139. https:\/\/doi.org\/10.1097\/HJH.0000000000000762","DOI":"10.1097\/HJH.0000000000000762"},{"key":"2708_CR151","doi-asserted-by":"publisher","unstructured":"Perazella MA. Trimethoprim-Induced Hyperkalaemia. Drug Saf. 2000;22:227\u201336. https:\/\/doi.org\/10.2165\/00002018-200022030-00006","DOI":"10.2165\/00002018-200022030-00006"},{"key":"2708_CR152","doi-asserted-by":"publisher","unstructured":"Baker M, Perazella MA. NSAIDs in CKD: Are They Safe? Am J Kidney Dis Off J Natl Kidney Found. 2020;76:546\u201357. https:\/\/doi.org\/10.1053\/j.ajkd.2020.03.023","DOI":"10.1053\/j.ajkd.2020.03.023"},{"key":"2708_CR153","doi-asserted-by":"publisher","unstructured":"Nash DM, Markle-Reid M, Brimble KS, McArthur E, Roshanov PS, Fink JC, u.\u202fa. Nonsteroidal anti-inflammatory drug use and risk of acute kidney injury and hyperkalemia in older adults: a\u00a0population-based study. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2019;34:1145\u201354. https:\/\/doi.org\/10.1093\/ndt\/gfz062","DOI":"10.1093\/ndt\/gfz062"},{"key":"2708_CR154","doi-asserted-by":"publisher","unstructured":"Armstrong MJ, Zhang K, Ye F, Klarenbach SW, Pannu NI. Population-Based Analysis of Nonsteroidal Anti-inflammatory Drug Prescription in Subjects With Chronic Kidney Disease. Can J Kidney Health Dis. 2023;10:20543581221149621. https:\/\/doi.org\/10.1177\/20543581221149621","DOI":"10.1177\/20543581221149621"},{"key":"2708_CR155","doi-asserted-by":"publisher","unstructured":"Ben Salem C, Badreddine A, Fathallah N, Slim R, Hmouda H. Drug-Induced Hyperkalemia. Drug Saf. 2014;37:677\u201392. https:\/\/doi.org\/10.1007\/s40264-014-0196-1","DOI":"10.1007\/s40264-014-0196-1"},{"key":"2708_CR156","unstructured":"Ngwenya B. UKKA Clinical Practice Guideline \u2013 Management of Hyperkalaemia in Adults \u2013 October 2023. 2023;"},{"key":"2708_CR157","doi-asserted-by":"publisher","unstructured":"Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, u.\u202fa. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543\u201351. https:\/\/doi.org\/10.1056\/NEJMoa040135","DOI":"10.1056\/NEJMoa040135"},{"key":"2708_CR158","doi-asserted-by":"publisher","unstructured":"Ellison DH, Terker AS, Gamba G. Potassium and Its Discontents: New Insight, New Treatments. J\u00a0Am Soc Nephrol JASN. 2016;27:981\u20139. https:\/\/doi.org\/10.1681\/ASN.2015070751","DOI":"10.1681\/ASN.2015070751"},{"key":"2708_CR159","doi-asserted-by":"publisher","unstructured":"Sousa AGP, Cabral JV de S, El-Feghaly WB, de Sousa LS, Nunes AB. Hyporeninemic hypoaldosteronism and diabetes mellitus: Pathophysiology assumptions, clinical aspects and implications for management. World J Diabetes. 2016;7:101\u201311. https:\/\/doi.org\/10.4239\/wjd.v7.i5.101","DOI":"10.4239\/wjd.v7.i5.101"},{"key":"2708_CR160","doi-asserted-by":"publisher","unstructured":"Perez GO, Pelleya R, Oster JR, Kem DC, Vaamonde CA. Blunted kaliuresis after an acute potassium load in patients with chronic renal failure. Kidney Int. 1983;24:656\u201362. https:\/\/doi.org\/10.1038\/ki.1983.208","DOI":"10.1038\/ki.1983.208"},{"key":"2708_CR161","doi-asserted-by":"publisher","unstructured":"Allon M, Dansby L, Shanklin N. Glucose modulation of the disposal of an acute potassium load in patients with end-stage renal disease. Am J Med. 1993;94:475\u201382. https:\/\/doi.org\/10.1016\/0002-9343(93)90081-Y","DOI":"10.1016\/0002-9343(93)90081-Y"},{"key":"2708_CR162","doi-asserted-by":"publisher","unstructured":"Schachter J, Harper PH, Radin ME, Caggiula AW, McDonald RH, Diven WF. Comparison of sodium and potassium intake with excretion. Hypertens Dallas Tex 1979. 1980;2:695\u20139. https:\/\/doi.org\/10.1161\/01.hyp.2.5.695","DOI":"10.1161\/01.hyp.2.5.695"},{"key":"2708_CR163","doi-asserted-by":"publisher","unstructured":"Tafesse E, Hurst M, Hoskin L, Badora K, Sugrue D, Qin L, u.\u202fa. Risk factors associated with the incidence and recurrence of hyperkalaemia in patients with cardiorenal conditions. Int J Clin Pract. 2021;75:e13941. https:\/\/doi.org\/10.1111\/ijcp.13941","DOI":"10.1111\/ijcp.13941"},{"key":"2708_CR164","doi-asserted-by":"publisher","unstructured":"Bakris G, Agiro A, Mu F, Cook EE, Greatsinger A, Sundar M, u.\u202fa. Consequences of Recurrent Hyperkalemia on Cardiovascular Outcomes and Mortality. JACC Adv. 2024;3:101331. https:\/\/doi.org\/10.1016\/j.jacadv.2024.101331","DOI":"10.1016\/j.jacadv.2024.101331"},{"key":"2708_CR165","doi-asserted-by":"publisher","unstructured":"Mulkerrin E, Epstein FH, Clark BA. Aldosterone responses to hyperkalemia in healthy elderly humans. J\u00a0Am Soc Nephrol JASN. 1995;6:1459\u201362. https:\/\/doi.org\/10.1681\/ASN.V651459","DOI":"10.1681\/ASN.V651459"},{"key":"2708_CR166","doi-asserted-by":"publisher","unstructured":"Kovesdy CP, Matsushita K, Sang Y, Brunskill NJ, Carrero JJ, Chodick G, u.\u202fa. Serum potassium and adverse outcomes across the range of kidney function: a\u00a0CKD Prognosis Consortium meta-analysis. Eur Heart J. 2018;39:1535\u201342. https:\/\/doi.org\/10.1093\/eurheartj\/ehy100","DOI":"10.1093\/eurheartj\/ehy100"},{"key":"2708_CR167","doi-asserted-by":"publisher","unstructured":"Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, u.\u202fa. Finerenone with Empagliflozin in Chronic Kidney Disease and Type\u00a02 Diabetes. N Engl J Med. 2025; https:\/\/doi.org\/10.1056\/NEJMoa2410659","DOI":"10.1056\/NEJMoa2410659"},{"key":"2708_CR168","doi-asserted-by":"publisher","unstructured":"Ferreira JP, Anker SD, Palmer BF, Pitt B, Rossing P, Ruilope LM, u.\u202fa. Incident hyperkalaemia risk model in chronic kidney disease and diabetes: the FIDELITY programme. Eur Heart J. 2025;ehaf258. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf258","DOI":"10.1093\/eurheartj\/ehaf258"},{"key":"2708_CR169","doi-asserted-by":"publisher","unstructured":"Xue C, Zhou C, Yang B, Ye X, Xu J, Lu Y, u.\u202fa. A\u00a0Nomogram to Identify Hyperkalemia Risk in Patients with Advanced CKD. Kidney360. 2022;3:1699\u2013709. https:\/\/doi.org\/10.34067\/KID.0004752022","DOI":"10.34067\/KID.0004752022"},{"key":"2708_CR170","doi-asserted-by":"publisher","unstructured":"Schoeber NHC, Linders M, Binkhorst M, De Boode W\u2011P, Draaisma JMT, Morsink M, u.\u202fa. Healthcare professionals\u2019 knowledge of the systematic ABCDE approach: a\u00a0cross-sectional study. BMC Emerg Med. 2022;22:202. https:\/\/doi.org\/10.1186\/s12873-022-00753-y","DOI":"10.1186\/s12873-022-00753-y"},{"key":"2708_CR171","doi-asserted-by":"publisher","unstructured":"Cort\u00e9s-Ort\u00edz A, Trujillo-Espinosa JA, Hern\u00e1ndez-Lozada JA, Gracia-Ramos AE. Sinus arrest consequence of moderate hyperkalemia: a\u00a0case report. Oxf Med Case Rep. 2025;2025:omaf059. https:\/\/doi.org\/10.1093\/omcr\/omaf059","DOI":"10.1093\/omcr\/omaf059"},{"key":"2708_CR172","doi-asserted-by":"publisher","unstructured":"Durfey N, Lehnhof B, Bergeson A, Durfey SNM, Leytin V, McAteer K, u.\u202fa. Severe Hyperkalemia: Can the Electrocardiogram Risk Stratify for Short-term Adverse Events? West J Emerg Med. 2017;18:963\u201371. https:\/\/doi.org\/10.5811\/westjem.2017.6.33033","DOI":"10.5811\/westjem.2017.6.33033"},{"key":"2708_CR173","doi-asserted-by":"publisher","unstructured":"Singer AJ, Thode HC, Peacock WF. Rapid correction of hyperkalemia is associated with reduced mortality in ED patients. Am J Emerg Med. 2020;38:2361\u20134. https:\/\/doi.org\/10.1016\/j.ajem.2019.12.012","DOI":"10.1016\/j.ajem.2019.12.012"},{"key":"2708_CR174","doi-asserted-by":"publisher","unstructured":"Lott C, Truhl\u00e1\u0159 A, Alfonzo A, Barelli A, Gonz\u00e1lez-Salvado V, Hinkelbein J, u.\u202fa. European Resuscitation Council Guidelines 2021: Cardiac arrest in special circumstances. Resuscitation. 2021;161:152\u2013219. https:\/\/doi.org\/10.1016\/j.resuscitation.2021.02.011","DOI":"10.1016\/j.resuscitation.2021.02.011"},{"key":"2708_CR175","doi-asserted-by":"publisher","unstructured":"Piktel JS, Wan X, Kouk S, Laurita KR, Wilson LD. Beneficial Effect of Calcium Treatment for Hyperkalemia Is Not Due to \u201cMembrane Stabilization\u201d. Crit Care Med. 2024;52:1499\u2013508. https:\/\/doi.org\/10.1097\/CCM.0000000000006376","DOI":"10.1097\/CCM.0000000000006376"},{"key":"2708_CR176","doi-asserted-by":"publisher","unstructured":"Robert T, Joseph A, Mesnard L. Calcium salt during hyperkalemia. Kidney Int. 2016;90:451\u20132. https:\/\/doi.org\/10.1016\/j.kint.2016.05.016","DOI":"10.1016\/j.kint.2016.05.016"},{"key":"2708_CR177","doi-asserted-by":"publisher","unstructured":"Davey M, Caldicott D. Calcium salts in management of hyperkalaemia. Emerg Med J EMJ. 2002;19:92\u20133. https:\/\/doi.org\/10.1136\/emj.19.1.92-a","DOI":"10.1136\/emj.19.1.92-a"},{"key":"2708_CR178","doi-asserted-by":"publisher","unstructured":"Vanden Hoek TL, Morrison LJ, Shuster M, Donnino M, Sinz E, Lavonas EJ, u.\u202fa. Part\u00a012: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122:S829\u2013861. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.971069","DOI":"10.1161\/CIRCULATIONAHA.110.971069"},{"key":"2708_CR179","doi-asserted-by":"publisher","unstructured":"Celebi Yamanoglu NG, Yamanoglu A. The effect of calcium gluconate in the treatment of hyperkalemia. Turk J Emerg Med. 2022;22:75\u201382. https:\/\/doi.org\/10.4103\/2452-2473.342812","DOI":"10.4103\/2452-2473.342812"},{"key":"2708_CR180","doi-asserted-by":"publisher","unstructured":"Zijlstra GJ. Challenging Dogma: Calcium Treatment in Hyperkalemia. Crit Care Med. 2025;53:e760\u20131. https:\/\/doi.org\/10.1097\/CCM.0000000000006456","DOI":"10.1097\/CCM.0000000000006456"},{"key":"2708_CR181","doi-asserted-by":"publisher","unstructured":"Eggertsen MA, Munch Johannsen C, Kovacevic A, Fink Vallentin M, M\u00f8rk Vammen L, Andersen LW, u.\u202fa. Sodium Bicarbonate and Calcium Chloride for the Treatment of Hyperkalemia-Induced Cardiac Arrest: A\u00a0Randomized, Blinded, Placebo-Controlled Animal Study. Crit Care Med. 2024;52:e67\u201378. https:\/\/doi.org\/10.1097\/CCM.0000000000006089","DOI":"10.1097\/CCM.0000000000006089"},{"key":"2708_CR182","doi-asserted-by":"publisher","unstructured":"Hack JB, Woody JH, Lewis DE, Brewer K, Meggs WJ. The effect of calcium chloride in treating hyperkalemia due to acute digoxin toxicity in a\u00a0porcine model. J\u00a0Toxicol Clin Toxicol. 2004;42:337\u201342. https:\/\/doi.org\/10.1081\/clt-120039538","DOI":"10.1081\/clt-120039538"},{"key":"2708_CR183","doi-asserted-by":"publisher","unstructured":"Vallentin MF, Povlsen AL, Granfeldt A, Terkelsen CJ, Andersen LW. Effect of calcium in patients with pulseless electrical activity and electrocardiographic characteristics potentially associated with hyperkalemia and ischemia-sub-study of the Calcium for Out-of-hospital Cardiac Arrest (COCA) trial. Resuscitation. 2022;181:150\u20137. https:\/\/doi.org\/10.1016\/j.resuscitation.2022.11.006","DOI":"10.1016\/j.resuscitation.2022.11.006"},{"key":"2708_CR184","doi-asserted-by":"publisher","unstructured":"Jessen MK, Andersen LW, Djakow J, Chong NK, Stankovic N, Staehr C, u.\u202fa. Pharmacological interventions for the acute treatment of hyperkalaemia: A\u00a0systematic review and meta-analysis. Resuscitation. 2025;208:110489. https:\/\/doi.org\/10.1016\/j.resuscitation.2025.110489","DOI":"10.1016\/j.resuscitation.2025.110489"},{"key":"2708_CR185","doi-asserted-by":"publisher","unstructured":"Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney Int. 1990;38:869\u201372. https:\/\/doi.org\/10.1038\/ki.1990.284","DOI":"10.1038\/ki.1990.284"},{"key":"2708_CR186","doi-asserted-by":"publisher","unstructured":"Harel Z, Kamel KS. Optimal Dose and Method of Administration of Intravenous Insulin in the Management of Emergency Hyperkalemia: A\u00a0Systematic Review. PloS One. 2016;11:e0154963. https:\/\/doi.org\/10.1371\/journal.pone.0154963","DOI":"10.1371\/journal.pone.0154963"},{"key":"2708_CR187","doi-asserted-by":"publisher","unstructured":"Dybdahl D, Roberson T, Rasor E, Kline L, Pershing M. Impact of a\u00a0Hyperkalemia Protocol Tailored to Glucose Concentration and Renal Function on Insulin-Induced Hypoglycemia in Patients with Low Pretreatment Glucose. J\u00a0Emerg Med. 2024;66:e421\u201331. https:\/\/doi.org\/10.1016\/j.jemermed.2023.12.001","DOI":"10.1016\/j.jemermed.2023.12.001"},{"key":"2708_CR188","doi-asserted-by":"publisher","unstructured":"Humphrey TJL, James G, Wilkinson IB, Hiemstra TF. Clinical outcomes associated with the emergency treatment of hyperkalaemia with intravenous insulin-dextrose. Eur J Intern Med. 2022;95:87\u201392. https:\/\/doi.org\/10.1016\/j.ejim.2021.09.018","DOI":"10.1016\/j.ejim.2021.09.018"},{"key":"2708_CR189","doi-asserted-by":"publisher","unstructured":"Truhl\u00e1\u0159 A, Deakin CD, Soar J, Khalifa GEA, Alfonzo A, Bierens JJLM, u.\u202fa. European Resuscitation Council Guidelines for Resuscitation 2015: Section\u00a04. Cardiac arrest in special circumstances. Resuscitation. 2015;95:148\u2013201. https:\/\/doi.org\/10.1016\/j.resuscitation.2015.07.017","DOI":"10.1016\/j.resuscitation.2015.07.017"},{"key":"2708_CR190","doi-asserted-by":"publisher","unstructured":"Robert T, Burbach M, Joseph A, Mesnard L. Sodium is the secret re-agent of bicarbonate therapy during hyperkalemia. Kidney Int. 2016;90:450\u20131. https:\/\/doi.org\/10.1016\/j.kint.2016.05.015","DOI":"10.1016\/j.kint.2016.05.015"},{"key":"2708_CR191","unstructured":"Joubert L, Radouco-Thomas C, Loiselle JM, Radouco-Thomas S, Turmel-Dorion L, Warren Y. A\u00a0study in human pharmacology: evaluation of four diuretics and a\u00a0placebo. Can Med Assoc J. 1968;99:57\u201363."},{"key":"2708_CR192","doi-asserted-by":"publisher","unstructured":"Nguyen PT, Kataria VK, Sam TR, Hooper K, Mehta AN. Comparison of Patiromer to Sodium Polystyrene Sulfonate in Acute Hyperkalemia. Hosp Pharm. 2022;57:359\u201364. https:\/\/doi.org\/10.1177\/00185787211037552","DOI":"10.1177\/00185787211037552"},{"key":"2708_CR193","doi-asserted-by":"publisher","unstructured":"Grewal D, Urip L, Hong LT. Evaluation of Monotherapy Sodium Zirconium Cyclosilicate Versus Sodium Polystyrene Sulfonate for Acute Hyperkalemia: A\u00a0Cohort Study. Hosp Pharm. 2024;00185787241287676. https:\/\/doi.org\/10.1177\/00185787241287676","DOI":"10.1177\/00185787241287676"},{"key":"2708_CR194","doi-asserted-by":"publisher","unstructured":"Rydell A, Thackrey C, Molki M, Mullins BP. Effectiveness of Patiromer Versus Sodium Zirconium Cyclosilicate for the Management of Acute Hyperkalemia. Ann Pharmacother. 2024;58:790\u20135. https:\/\/doi.org\/10.1177\/10600280231209968","DOI":"10.1177\/10600280231209968"},{"key":"2708_CR195","doi-asserted-by":"publisher","unstructured":"Hagan AE, Farrington CA, Wall GC, Belz MM. Sodium polystyrene sulfonate for the treatment of acute hyperkalemia: a\u00a0retrospective study. Clin Nephrol. 2016;85:38\u201343. https:\/\/doi.org\/10.5414\/CN108628","DOI":"10.5414\/CN108628"},{"key":"2708_CR196","doi-asserted-by":"publisher","unstructured":"Rafique Z, Liu M, Staggers KA, Minard CG, Peacock WF. Patiromer for Treatment of Hyperkalemia in the Emergency Department: A\u00a0Pilot Study. Acad Emerg Med Off J Soc Acad Emerg Med. 2020;27:54\u201360. https:\/\/doi.org\/10.1111\/acem.13868","DOI":"10.1111\/acem.13868"},{"key":"2708_CR197","doi-asserted-by":"publisher","unstructured":"Shrestha DB, Budhathoki P, Sedhai YR, Baniya R, Cable CA, Kashiouris MG, u.\u202fa. Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A\u00a0Systematic Review and Meta-Analysis. Curr Ther Res Clin Exp. 2021;95:100635. https:\/\/doi.org\/10.1016\/j.curtheres.2021.100635","DOI":"10.1016\/j.curtheres.2021.100635"},{"key":"2708_CR198","doi-asserted-by":"publisher","unstructured":"Kashihara N, Kumeda Y, Higashino Y, Maeda Y, Kaneko Y, Kanai H, u.\u202fa. Efficacy and safety of patiromer for non-dialysis and dialysis patients with hyperkalemia: the randomized, placebo-controlled and long-term study. Clin Exp Nephrol. 2025;29:548\u201359. https:\/\/doi.org\/10.1007\/s10157-024-02585-5","DOI":"10.1007\/s10157-024-02585-5"},{"key":"2708_CR199","doi-asserted-by":"publisher","unstructured":"Di Palo KE, Sinnett MJ, Goriacko P. Assessment of Patiromer Monotherapy for Hyperkalemia in an Acute Care Setting. JAMA Netw Open. 2022;5:e2145236. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.45236","DOI":"10.1001\/jamanetworkopen.2021.45236"},{"key":"2708_CR200","doi-asserted-by":"publisher","unstructured":"Rossignol P, Pitt B. Sodium polystyrene is unsafe and should not be prescribed for the treatment of hyperkalaemia: primum non nocere! Clin Kidney J. 2023;16:1221\u20135. https:\/\/doi.org\/10.1093\/ckj\/sfad090","DOI":"10.1093\/ckj\/sfad090"},{"key":"2708_CR201","doi-asserted-by":"publisher","unstructured":"Peacock WF, Rafique Z, Vishnevskiy K, Michelson E, Vishneva E, Zvereva T, u.\u202fa. Emergency Potassium Normalization Treatment Including Sodium Zirconium Cyclosilicate: A\u00a0Phase\u00a0II, Randomized, Double-blind, Placebo-controlled Study (ENERGIZE). Acad Emerg Med Off J Soc Acad Emerg Med. 2020;27:475\u201386. https:\/\/doi.org\/10.1111\/acem.13954","DOI":"10.1111\/acem.13954"},{"key":"2708_CR202","doi-asserted-by":"publisher","unstructured":"Ca\u00f1as AE, Troutt HR, Jiang L, Tonthat S, Darwish O, Ferrey A, u.\u202fa. A\u00a0randomized study to compare oral potassium binders in the treatment of acute hyperkalemia. BMC Nephrol. 2023;24:89. https:\/\/doi.org\/10.1186\/s12882-023-03145-x","DOI":"10.1186\/s12882-023-03145-x"},{"key":"2708_CR203","doi-asserted-by":"publisher","unstructured":"Rafique Z, Budden J, Quinn CM, Duanmu Y, Safdar B, Bischof JJ, u.\u202fa. Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): design of a\u00a0multicentre, randomised, double-blind, placebo-controlled, parallel-group study. BMJ Open. 2023;13:e071311. https:\/\/doi.org\/10.1136\/bmjopen-2022-071311","DOI":"10.1136\/bmjopen-2022-071311"},{"key":"2708_CR204","doi-asserted-by":"publisher","unstructured":"Desai NR, Kammerer J, Budden J, Olopoenia A, Tysseling A, Gordon A. The Association of Heart Failure and Edema Events between Patients Initiating Sodium Zirconium Cyclosilicate or Patiromer. Kidney360. 2024;5:1835\u201343. https:\/\/doi.org\/10.34067\/KID.0000000586","DOI":"10.34067\/KID.0000000586"},{"key":"2708_CR205","doi-asserted-by":"publisher","unstructured":"Zhang Y, Xu R, Wang F, Liu Y, Xu J, Zhao N, u.\u202fa. Effects and Safety of a\u00a0Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a\u00a0Systematic Review and Meta-Analysis. Cardiovasc Drugs Ther. 2021;35:1057\u201366. https:\/\/doi.org\/10.1007\/s10557-020-07134-2","DOI":"10.1007\/s10557-020-07134-2"},{"key":"2708_CR206","doi-asserted-by":"publisher","unstructured":"Nakayama T, Kaneko H, Suzuki Y, Okada A, Morita H, Fujiu K, u.\u202fa. Sodium Polystyrene Sulfonate and Heart Failure Risk: A\u00a0Comparative Study With Calcium Polystyrene Sulfonate. Nephrol Carlton Vic. 2025;30:e70117. https:\/\/doi.org\/10.1111\/nep.70117","DOI":"10.1111\/nep.70117"},{"key":"2708_CR207","doi-asserted-by":"publisher","unstructured":"Zhuo M, Kim SC, Patorno E, Paik JM. Risk of Hospitalization for Heart Failure in Patients With Hyperkalemia Treated With Sodium Zirconium Cyclosilicate Versus Patiromer. J\u00a0Card Fail. 2022;28:1414\u201323. https:\/\/doi.org\/10.1016\/j.cardfail.2022.04.003","DOI":"10.1016\/j.cardfail.2022.04.003"},{"key":"2708_CR208","doi-asserted-by":"publisher","unstructured":"Amin AN, Menoyo J, Singh B, Kim CS. Efficacy and safety of sodium zirconium cyclosilicate in patients with baseline serum potassium level \u2265\u202f5.5\u202fmmol\/L:\u00a0pooled analysis from two phase\u00a03\u00a0trials. BMC Nephrol. 2019;20:440. https:\/\/doi.org\/10.1186\/s12882-019-1611-8","DOI":"10.1186\/s12882-019-1611-8"},{"key":"2708_CR209","doi-asserted-by":"publisher","unstructured":"Di Palo KE, Sinnett MJ, Goriacko P. Assessment of Patiromer Monotherapy for Hyperkalemia in an Acute Care Setting. JAMA Netw Open. 2022;5:e2145236. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.45236","DOI":"10.1001\/jamanetworkopen.2021.45236"},{"key":"2708_CR210","doi-asserted-by":"publisher","unstructured":"Fravel MA, Meaney CJ, Noureddine L. Management of Hyperkalemia in Patients with Chronic Kidney Disease Using Renin Angiotensin Aldosterone System Inhibitors. Curr Hypertens Rep. 2023;25:395\u2013404. https:\/\/doi.org\/10.1007\/s11906-023-01265-1","DOI":"10.1007\/s11906-023-01265-1"},{"key":"2708_CR211","doi-asserted-by":"publisher","unstructured":"Arampatzis S, Funk G\u2011C, Leichtle A, Fiedler G, Schwarz C, Zimmermann H, u.\u202fa. Impact of diuretic therapy-associated electrolyte disorders present on admission to the emergency department: A\u00a0cross-sectional analysis. BMC Med. 2013;11:83. https:\/\/doi.org\/10.1186\/1741-7015-11-83","DOI":"10.1186\/1741-7015-11-83"},{"key":"2708_CR212","doi-asserted-by":"publisher","unstructured":"Te Dorsthorst RPM, Hendrikse J, Vervoorn MT, van Weperen VYH, van der Heyden MAG. Review of case reports on hyperkalemia induced by dietary intake: not restricted to chronic kidney disease patients. Eur J Clin Nutr. 2019;73:38\u201345. https:\/\/doi.org\/10.1038\/s41430-018-0154-6","DOI":"10.1038\/s41430-018-0154-6"},{"key":"2708_CR213","doi-asserted-by":"publisher","unstructured":"Lim CC, Tan NC, Teo EPS, Kadir HBA, Kwek JL, Bee YM, u.\u202fa. Non-Steroidal Anti-Inflammatory Drugs and Risk of Acute Kidney Injury and Hyperkalemia in Older Adults: A\u00a0Retrospective Cohort Study and External Validation of a\u00a0Clinical Risk Model. Drugs Aging. 2022;39:75\u201382. https:\/\/doi.org\/10.1007\/s40266-021-00907-w","DOI":"10.1007\/s40266-021-00907-w"},{"key":"2708_CR214","doi-asserted-by":"publisher","unstructured":"Butterhoff MH, Derijks HJ, Hermens W, van der Linden PD. Sulfamethoxazole-Trimethoprim-Induced Hyperkalemia in Hospitalized Patients Using Potassium-Sparing Drugs: An Observational Study. Sr Care Pharm. 2024;39:259\u201366. https:\/\/doi.org\/10.4140\/TCP.n.2024.259","DOI":"10.4140\/TCP.n.2024.259"},{"key":"2708_CR215","doi-asserted-by":"publisher","unstructured":"Naseralallah L, Nasrallah D, Koraysh S, Aboelbaha S, Hussain TA. A\u00a0Comparative Study Assessing the Incidence and Degree of Hyperkalemia in Patients on Unfractionated Heparin versus Low-Molecular Weight Heparin. Clin Pharmacol Adv Appl. 2024;16:33\u201340. https:\/\/doi.org\/10.2147\/CPAA.S487288","DOI":"10.2147\/CPAA.S487288"},{"key":"2708_CR216","doi-asserted-by":"publisher","unstructured":"Hwang YJ, Muanda FT, McArthur E, Weir MA, Sontrop JM, Lam NN, u.\u202fa. Trimethoprim-sulfamethoxazole and the risk of a\u00a0hospital encounter with hyperkalemia: a\u00a0matched population-based cohort study. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2023;38:1459\u201368. https:\/\/doi.org\/10.1093\/ndt\/gfac282","DOI":"10.1093\/ndt\/gfac282"},{"key":"2708_CR217","doi-asserted-by":"publisher","unstructured":"Pirklbauer M. Dialysevorschrift. Nephrol. 2023;18:131\u20137. https:\/\/doi.org\/10.1007\/s11560-023-00632-y","DOI":"10.1007\/s11560-023-00632-y"},{"key":"2708_CR218","doi-asserted-by":"publisher","unstructured":"Pirklbauer M. Hemodialysis treatment in patients with severe electrolyte disorders: Management of hyperkalemia and hyponatremia. Hemodial Int Int Symp Home Hemodial. 2020;24:282\u20139. https:\/\/doi.org\/10.1111\/hdi.12845","DOI":"10.1111\/hdi.12845"},{"key":"2708_CR219","doi-asserted-by":"publisher","unstructured":"Blumberg A, Roser HW, Zehnder C, M\u00fcller-Brand J.\u00a0Plasma potassium in patients with terminal renal failure during and after haemodialysis; relationship with dialytic potassium removal and total body potassium. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 1997;12:1629\u201334. https:\/\/doi.org\/10.1093\/ndt\/12.8.1629","DOI":"10.1093\/ndt\/12.8.1629"},{"key":"2708_CR220","doi-asserted-by":"publisher","unstructured":"D\u00e9pret F, Peacock WF, Liu KD, Rafique Z, Rossignol P, Legrand M.\u00a0Management of hyperkalemia in the acutely ill patient. Ann Intensive Care. 2019;9:32. https:\/\/doi.org\/10.1186\/s13613-019-0509-8","DOI":"10.1186\/s13613-019-0509-8"},{"key":"2708_CR221","doi-asserted-by":"publisher","unstructured":"Garg N, Kumar V, Sohal PM, Jain D, Jain A, Makkar V, u.\u202fa. Efficacy and Outcome of Intermittent Peritoneal Dialysis in Patients with Acute Kidney Injury: A\u00a0Single-Center Experience. Saudi J Kidney Dis Transplant. 2020;31:423. https:\/\/doi.org\/10.4103\/1319-2442.284017","DOI":"10.4103\/1319-2442.284017"},{"key":"2708_CR222","unstructured":"Urgent initiation of hemodialysis versus peritoneal dialysis in severe hyperkalemia: a\u00a0prospective study | Clinical Kidney Journal | Oxford Academic [Internet]. [zitiert 29.\u00a0November 2025]. https:\/\/academic.oup.com\/ckj\/advance-article\/doi\/10.1093\/ckj\/sfaf343\/8316135. Zugegriffen 29\u00a0Nov 2025"},{"key":"2708_CR223","doi-asserted-by":"publisher","unstructured":"Houz\u00e9 P, Baud FJ, Raphalen J\u2011H, Winchenne A, Moreira S, Gault P, u.\u202fa. Continuous renal replacement therapy in the treatment of severe hyperkalemia: An in vitro study. Int J Artif Organs. SAGE Publications Ltd STM; 2020;43:87\u201393. https:\/\/doi.org\/10.1177\/0391398819865748","DOI":"10.1177\/0391398819865748"},{"key":"2708_CR224","doi-asserted-by":"publisher","unstructured":"Hirve AA, Repp AB, Burgess L\u2011AK. Things We Do for No ReasonTM: Obtaining an electrocardiogram for managing mild hyperkalemia in hospitalized adults. J\u00a0Hosp Med. 2024;19:841\u20134. https:\/\/doi.org\/10.1002\/jhm.13288","DOI":"10.1002\/jhm.13288"},{"key":"2708_CR225","doi-asserted-by":"publisher","unstructured":"Mahoney BA, Smith W a. D, Lo DS, Tsoi K, Tonelli M, Clase CM. Emergency interventions for hyperkalaemia. Cochrane Database Syst Rev. 2005;2005:CD003235. https:\/\/doi.org\/10.1002\/14651858.CD003235.pub2","DOI":"10.1002\/14651858.CD003235.pub2"},{"key":"2708_CR226","doi-asserted-by":"publisher","unstructured":"D\u00e9pret F, Peacock WF, Liu KD, Rafique Z, Rossignol P, Legrand M.\u00a0Management of hyperkalemia in the acutely ill patient. Ann Intensive Care. 2019;9:32. https:\/\/doi.org\/10.1186\/s13613-019-0509-8","DOI":"10.1186\/s13613-019-0509-8"},{"key":"2708_CR227","doi-asserted-by":"publisher","unstructured":"Montford JR, Linas S. How Dangerous Is Hyperkalemia? J\u00a0Am Soc Nephrol JASN. 2017;28:3155\u201365. https:\/\/doi.org\/10.1681\/ASN.2016121344","DOI":"10.1681\/ASN.2016121344"},{"key":"2708_CR228","doi-asserted-by":"publisher","unstructured":"Obi Y, Thomas F, Dashputre AA, Goedecke P, Kovesdy CP. Long-term Patiromer Use and Outcomes Among US Veterans With Hyperkalemia and CKD: A\u00a0Propensity-Matched Cohort Study. Kidney Med. 2024;6:100757. https:\/\/doi.org\/10.1016\/j.xkme.2023.100757","DOI":"10.1016\/j.xkme.2023.100757"},{"key":"2708_CR229","doi-asserted-by":"publisher","unstructured":"Weir MR, Bakris GL, Gross C, Mayo MR, Garza D, Stasiv Y, u.\u202fa. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney Int. 2016;90:696\u2013704. https:\/\/doi.org\/10.1016\/j.kint.2016.04.019","DOI":"10.1016\/j.kint.2016.04.019"},{"key":"2708_CR230","doi-asserted-by":"publisher","unstructured":"Ramos CI, Gonz\u00e1lez-Ortiz A, Espinosa-Cuevas A, Avesani CM, Carrero JJ, Cuppari L. Does dietary potassium intake associate with hyperkalemia in patients with chronic kidney disease? Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2021;36:2049\u201357. https:\/\/doi.org\/10.1093\/ndt\/gfaa232","DOI":"10.1093\/ndt\/gfaa232"},{"key":"2708_CR231","doi-asserted-by":"publisher","unstructured":"Bernier-Jean A, Wong G, Saglimbene V, Ruospo M, Palmer SC, Natale P, u.\u202fa. Dietary Potassium Intake and All-Cause Mortality in Adults Treated with Hemodialysis. Clin J Am Soc Nephrol CJASN. 2021;16:1851\u201361. https:\/\/doi.org\/10.2215\/CJN.08360621","DOI":"10.2215\/CJN.08360621"},{"key":"2708_CR232","doi-asserted-by":"publisher","unstructured":"Tyson CC, Lin P\u2011H, Corsino L, Batch BC, Allen J, Sapp S, u.\u202fa. Short-term effects of the DASH diet in adults with moderate chronic kidney disease: a\u00a0pilot feeding study. Clin Kidney J. 2016;9:592\u20138. https:\/\/doi.org\/10.1093\/ckj\/sfw046","DOI":"10.1093\/ckj\/sfw046"},{"key":"2708_CR233","doi-asserted-by":"publisher","unstructured":"Saglimbene VM, Wong G, Ruospo M, Palmer SC, Garcia-Larsen V, Natale P, u.\u202fa. Fruit and Vegetable Intake and Mortality in Adults undergoing Maintenance Hemodialysis. Clin J Am Soc Nephrol CJASN. 2019;14:250\u201360. https:\/\/doi.org\/10.2215\/CJN.08580718","DOI":"10.2215\/CJN.08580718"},{"key":"2708_CR234","doi-asserted-by":"publisher","unstructured":"Borrelli S, De Nicola L, Minutolo R, Conte G, Chiodini P, Cupisti A, u.\u202fa. Current Management of Hyperkalemia in Non-Dialysis CKD: Longitudinal Study of Patients Receiving Stable Nephrology Care. Nutrients. 2021;13:942. https:\/\/doi.org\/10.3390\/nu13030942","DOI":"10.3390\/nu13030942"},{"key":"2708_CR235","doi-asserted-by":"publisher","unstructured":"Turban S, Juraschek SP, Miller ER, Anderson CAM, White K, Charleston J, u.\u202fa. Randomized Trial on the Effects of Dietary Potassium on Blood Pressure and Serum Potassium Levels in Adults with Chronic Kidney Disease. Nutrients. 2021;13:2678. https:\/\/doi.org\/10.3390\/nu13082678","DOI":"10.3390\/nu13082678"},{"key":"2708_CR236","doi-asserted-by":"publisher","unstructured":"Gritter M, Wouda RD, Yeung SMH, Wie\u00ebrs MLA, Geurts F, de Ridder MAJ, u.\u202fa. Effects of Short-Term Potassium Chloride Supplementation in Patients with CKD. J\u00a0Am Soc Nephrol JASN. 2022;33:1779\u201389. https:\/\/doi.org\/10.1681\/ASN.2022020147","DOI":"10.1681\/ASN.2022020147"},{"key":"2708_CR237","doi-asserted-by":"publisher","unstructured":"Rowan CG, Agiro A, Chan KA, Colman E, White K, Desai P, u.\u202fa. Hyperkalemia Recurrence Following Medical Nutrition Therapy in Patients with Stage\u00a03\u20114 Chronic Kidney Disease: The REVOLUTIONIZE I Real-World Study. Adv Ther. 2024;41:2381\u201398. https:\/\/doi.org\/10.1007\/s12325-024-02835-8","DOI":"10.1007\/s12325-024-02835-8"},{"key":"2708_CR238","doi-asserted-by":"publisher","unstructured":"Goraya N, Simoni J, Jo C\u2011H, Wesson DE. A\u00a0comparison of treating metabolic acidosis in CKD stage\u00a04 hypertensive kidney disease with fruits and vegetables or sodium bicarbonate. Clin J Am Soc Nephrol CJASN. 2013;8:371\u201381. https:\/\/doi.org\/10.2215\/CJN.02430312","DOI":"10.2215\/CJN.02430312"},{"key":"2708_CR239","doi-asserted-by":"publisher","unstructured":"Cupisti A, Kovesdy CP, D\u2019Alessandro C, Kalantar-Zadeh K. Dietary Approach to Recurrent or Chronic Hyperkalaemia in Patients with Decreased Kidney Function. Nutrients. 2018;10:261. https:\/\/doi.org\/10.3390\/nu10030261","DOI":"10.3390\/nu10030261"},{"key":"2708_CR240","doi-asserted-by":"publisher","unstructured":"Biruete A, Anderson C, Bernier-Jean A, Clase CM, Clegg D, Crews DC, u.\u202fa. ASN Kidney Health Guidance on Potassium and Phosphorus Food Additives. J\u00a0Am Soc Nephrol JASN. 2025; https:\/\/doi.org\/10.1681\/ASN.0000000873","DOI":"10.1681\/ASN.0000000873"},{"key":"2708_CR241","doi-asserted-by":"publisher","unstructured":"Iman Y, Balshaw R, Alexiuk M, Hingwala J, Cahill L, Mollard R, u.a. Dietary potassium liberalization with fruit and vegetables versus potassium restriction in people with chronic kidney disease (DK-Lib CKD): a clinical trial protocol. BMC Nephrol. 2023 24(1):301. doi: https:\/\/doi.org\/10.1186\/s12882-023-03354-4.","DOI":"10.1186\/s12882-023-03354-4"},{"key":"2708_CR242","doi-asserted-by":"publisher","unstructured":"An J, Zhou H, Ni L, Harrision TN, Wei R, Agiro A, u.\u202fa. Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes. Am J Nephrol. 2023;54:258\u201367. https:\/\/doi.org\/10.1159\/000531102","DOI":"10.1159\/000531102"},{"key":"2708_CR243","doi-asserted-by":"publisher","unstructured":"Leon SJ, Whitlock R, Rigatto C, Komenda P, Bohm C, Sucha E, u.\u202fa. Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A\u00a0Population-Based Cohort Study. Am J Kidney Dis Off J Natl Kidney Found. 2022;80:164\u2013173.e1. https:\/\/doi.org\/10.1053\/j.ajkd.2022.01.002","DOI":"10.1053\/j.ajkd.2022.01.002"},{"key":"2708_CR244","doi-asserted-by":"publisher","unstructured":"Li L, Harrison SD, Cope MJ, Park C, Lee L, Salaymeh F, u.\u202fa. Mechanism of Action and Pharmacology of Patiromer, a\u00a0Nonabsorbed Cross-Linked Polymer That Lowers Serum Potassium Concentration in Patients With Hyperkalemia. J\u00a0Cardiovasc Pharmacol Ther. 2016;21:456\u201365. https:\/\/doi.org\/10.1177\/1074248416629549","DOI":"10.1177\/1074248416629549"},{"key":"2708_CR245","doi-asserted-by":"publisher","unstructured":"Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, u.\u202fa. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. JAMA. 2015;314:151\u201361. https:\/\/doi.org\/10.1001\/jama.2015.7446","DOI":"10.1001\/jama.2015.7446"},{"key":"2708_CR246","doi-asserted-by":"publisher","unstructured":"Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, u.\u202fa. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372:211\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1410853","DOI":"10.1056\/NEJMoa1410853"},{"key":"2708_CR247","doi-asserted-by":"publisher","unstructured":"Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, u.\u202fa. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a\u00a0phase\u00a02, randomised, double-blind, placebo-controlled trial. Lancet Lond Engl. 2019;394:1540\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(19)32135-X","DOI":"10.1016\/S0140-6736(19)32135-X"},{"key":"2708_CR248","doi-asserted-by":"publisher","unstructured":"Roger SD, Lavin PT, Lerma EV, McCullough PA, Butler J, Spinowitz BS, u.\u202fa. Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild\/moderate versus severe\/end-stage chronic kidney disease: comparative results from an open-label, Phase\u00a03\u00a0study. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2021;36:137\u201350. https:\/\/doi.org\/10.1093\/ndt\/gfz285","DOI":"10.1093\/ndt\/gfz285"},{"key":"2708_CR249","doi-asserted-by":"publisher","unstructured":"Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, u.\u202fa. Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients With Hyperkalemia: The HARMONIZE Randomized Clinical Trial. JAMA. 2014;312:2223\u201333. https:\/\/doi.org\/10.1001\/jama.2014.15688","DOI":"10.1001\/jama.2014.15688"},{"key":"2708_CR250","doi-asserted-by":"publisher","unstructured":"Zannad F, Hsu B\u2011G, Maeda Y, Shin SK, Vishneva EM, Rensfeldt M, u.\u202fa. Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia: the randomized, placebo-controlled HARMONIZE-Global study. ESC Heart Fail. 2020;7:55\u201365. https:\/\/doi.org\/10.1002\/ehf2.12561","DOI":"10.1002\/ehf2.12561"},{"key":"2708_CR251","doi-asserted-by":"publisher","unstructured":"Spinowitz BS, Fishbane S, Pergola PE, Roger SD, Lerma EV, Butler J, u.\u202fa. Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A\u00a012-Month Phase\u00a03\u00a0Study. Clin J Am Soc Nephrol CJASN. 2019;14:798\u2013809. https:\/\/doi.org\/10.2215\/CJN.12651018","DOI":"10.2215\/CJN.12651018"},{"key":"2708_CR252","doi-asserted-by":"publisher","unstructured":"Ash SR, Batlle D, Kendrick J, Oluwatosin Y, Kooienga L, Eudicone JM, u.\u202fa. Sodium Zirconium Cyclosilicate in CKD, Hyperkalemia, and Metabolic Acidosis: NEUTRALIZE Randomized Study. Kidney360. 2024;5:812\u201320. https:\/\/doi.org\/10.34067\/KID.0000000000000446","DOI":"10.34067\/KID.0000000000000446"},{"key":"2708_CR253","unstructured":"Lokelma | European Medicines Agency (EMA) [Internet]. 2018 [zitiert 2.\u00a0Oktober 2025]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lokelma. Zugegriffen 2 Okt 2025"},{"key":"2708_CR254","doi-asserted-by":"publisher","unstructured":"Avesani CM, Heimb\u00fcrger O, Rubin C, Sallstrom T, F\u00e1xen-Irving G, Lindholm B, u.\u202fa. Plant-based diet in hyperkalemic chronic kidney disease patients receiving sodium zirconium cyclosilicate: a\u00a0feasibility clinical trial. Am J Clin Nutr. 2024;120:719\u201326. https:\/\/doi.org\/10.1016\/j.ajcnut.2024.06.025","DOI":"10.1016\/j.ajcnut.2024.06.025"},{"key":"2708_CR255","doi-asserted-by":"publisher","unstructured":"Laureati P, Xu Y, Trevisan M, Schalin L, Mariani I, Bellocco R, u.\u202fa. Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a\u00a0nationwide study. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2020;35:1518\u201326. https:\/\/doi.org\/10.1093\/ndt\/gfz150","DOI":"10.1093\/ndt\/gfz150"},{"key":"2708_CR256","doi-asserted-by":"publisher","unstructured":"Rossignol P, Pitt B. Sodium polystyrene is unsafe and should not be prescribed for the treatment of hyperkalaemia: primum non nocere! Clin Kidney J. 2023;16:1221\u20135. https:\/\/doi.org\/10.1093\/ckj\/sfad090","DOI":"10.1093\/ckj\/sfad090"},{"key":"2708_CR257","doi-asserted-by":"publisher","unstructured":"Carrero JJ, Sood MM, Gonzalez-Ortiz A, Clase CM. Pharmacological strategies to manage hyperkalaemia: out with the old, in with the new? Not so fast\u2026. Clin Kidney J. 2023;16:1213\u201320. https:\/\/doi.org\/10.1093\/ckj\/sfad089","DOI":"10.1093\/ckj\/sfad089"},{"key":"2708_CR258","doi-asserted-by":"publisher","unstructured":"Jaques DA, Stucker F, Ernandez T, Alves C, Martin P\u2011Y, De Seigneux S, u.\u202fa. Comparative efficacy of patiromer and sodium polystyrene sulfonate on potassium levels in chronic haemodialysis patients: a\u00a0randomized crossover trial. Clin Kidney J. 2022;15:1908\u201314. https:\/\/doi.org\/10.1093\/ckj\/sfac129","DOI":"10.1093\/ckj\/sfac129"},{"key":"2708_CR259","doi-asserted-by":"publisher","unstructured":"Noel JA, Bota SE, Petrcich W, Garg AX, Carrero JJ, Harel Z, u.\u202fa. Risk of Hospitalization for Serious Adverse Gastrointestinal Events Associated With Sodium Polystyrene Sulfonate Use in Patients of Advanced Age. JAMA Intern Med. 2019;179:1025\u201333. https:\/\/doi.org\/10.1001\/jamainternmed.2019.0631","DOI":"10.1001\/jamainternmed.2019.0631"},{"key":"2708_CR260","doi-asserted-by":"publisher","unstructured":"Holleck JL, Han L, Skanderson M, Bastian LA, Gunderson CG, Brandt CA, u.\u202fa. Risk of Serious Adverse Gastrointestinal Events with Potassium Binders in Hospitalized Patients: A\u00a0National Study. J\u00a0Gen Intern Med. 2025;40:518\u201324. https:\/\/doi.org\/10.1007\/s11606-024-08979-1","DOI":"10.1007\/s11606-024-08979-1"},{"key":"2708_CR261","doi-asserted-by":"publisher","unstructured":"Palmer BF, Clegg DJ. Treatment of Abnormalities of Potassium Homeostasis in CKD. Adv Chronic Kidney Dis. 2017;24:319\u201324. https:\/\/doi.org\/10.1053\/j.ackd.2017.06.001","DOI":"10.1053\/j.ackd.2017.06.001"},{"key":"2708_CR262","doi-asserted-by":"publisher","unstructured":"Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, u.\u202fa. Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease. N Engl J Med. 2021;385:2507\u201319. https:\/\/doi.org\/10.1056\/NEJMoa2110730","DOI":"10.1056\/NEJMoa2110730"},{"key":"2708_CR263","doi-asserted-by":"publisher","unstructured":"Trull\u00e0s JC, Morales-Rull JL, Casado J, Carrera-Izquierdo M, S\u00e1nchez-Marteles M, Conde-Martel A, u.\u202fa. Combining loop and thiazide diuretics for acute heart failure across the estimated glomerular filtration rate spectrum: a\u00a0post-hoc analysis of the CLOROTIC trial. Eur J Heart Fail. 2023; https:\/\/doi.org\/10.1002\/ejhf.2988","DOI":"10.1002\/ejhf.2988"},{"key":"2708_CR264","doi-asserted-by":"publisher","unstructured":"Ellison DH. Clinical Pharmacology in Diuretic Use. Clin J Am Soc Nephrol CJASN. 2019;14:1248\u201357. https:\/\/doi.org\/10.2215\/CJN.09630818","DOI":"10.2215\/CJN.09630818"},{"key":"2708_CR265","doi-asserted-by":"publisher","unstructured":"Provenzano M, Jongs N, Vart P, Stef\u00e1nsson BV, Chertow GM, Langkilde AM, u.\u202fa. The Kidney Protective Effects of the Sodium-Glucose Cotransporter\u20112 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists. Kidney Int Rep. 2022;7:436\u201343. https:\/\/doi.org\/10.1016\/j.ekir.2021.12.013","DOI":"10.1016\/j.ekir.2021.12.013"},{"key":"2708_CR266","doi-asserted-by":"publisher","unstructured":"Neuen BL, Oshima M, Agarwal R, Arnott C, Cherney DZ, Edwards R, u.\u202fa. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type\u00a02 Diabetes: A\u00a0Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. Circulation. American Heart Association; 2022;145:1460\u201370. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.057736","DOI":"10.1161\/CIRCULATIONAHA.121.057736"},{"key":"2708_CR267","doi-asserted-by":"publisher","unstructured":"Charlwood C, Chudasama J, Darling AL, Logan Ellis H, Whyte MB. Effect of sodium-glucose co-transporter 2\u00a0inhibitors on plasma potassium: A\u00a0meta-analysis. Diabetes Res Clin Pract. 2023;196:110239. https:\/\/doi.org\/10.1016\/j.diabres.2023.110239","DOI":"10.1016\/j.diabres.2023.110239"},{"key":"2708_CR268","doi-asserted-by":"publisher","unstructured":"Albakr RB, Sridhar VS, Cherney DZI. Novel Therapies in Diabetic Kidney Disease and Risk of Hyperkalemia: A\u00a0Review of the Evidence From Clinical Trials. Am J Kidney Dis Off J Natl Kidney Found. 2023;82:737\u201342. https:\/\/doi.org\/10.1053\/j.ajkd.2023.04.015","DOI":"10.1053\/j.ajkd.2023.04.015"},{"key":"2708_CR269","doi-asserted-by":"publisher","unstructured":"Sumida K, Dashputre AA, Potukuchi PK, Thomas F, Obi Y, Molnar MZ, u.\u202fa. Laxative Use and Risk of Dyskalemia in Patients with Advanced CKD Transitioning to Dialysis. J\u00a0Am Soc Nephrol JASN. 2021;32:950\u20139. https:\/\/doi.org\/10.1681\/ASN.2020081120","DOI":"10.1681\/ASN.2020081120"},{"key":"2708_CR270","doi-asserted-by":"publisher","unstructured":"de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate Supplementation Slows Progression of CKD and Improves Nutritional Status. J\u00a0Am Soc Nephrol JASN. 2009;20:2075\u201384. https:\/\/doi.org\/10.1681\/ASN.2008111205","DOI":"10.1681\/ASN.2008111205"},{"key":"2708_CR271","doi-asserted-by":"publisher","unstructured":"BiCARB study group. Clinical and cost-effectiveness of oral sodium bicarbonate therapy for older patients with chronic kidney disease and low-grade acidosis (BiCARB): a\u00a0pragmatic randomised, double-blind, placebo-controlled trial. BMC Med. 2020;18:91. https:\/\/doi.org\/10.1186\/s12916-020-01542-9","DOI":"10.1186\/s12916-020-01542-9"},{"key":"2708_CR272","doi-asserted-by":"publisher","unstructured":"Shi H, Su X, Yan B, Li C, Wang L. Effects of oral alkali drug therapy on clinical outcomes in pre-dialysis chronic kidney disease patients: a\u00a0systematic review and meta-analysis. Ren Fail. 2022;44:106\u201315. https:\/\/doi.org\/10.1080\/0886022X.2021.2023023","DOI":"10.1080\/0886022X.2021.2023023"},{"key":"2708_CR273","doi-asserted-by":"publisher","unstructured":"Pun PH, Middleton JP. Dialysate Potassium, Dialysate Magnesium, and Hemodialysis Risk. J\u00a0Am Soc Nephrol JASN. 2017;28:3441\u201351. https:\/\/doi.org\/10.1681\/ASN.2017060640","DOI":"10.1681\/ASN.2017060640"},{"key":"2708_CR274","doi-asserted-by":"publisher","unstructured":"Musso CG. Potassium metabolism in patients with chronic kidney disease. Part\u00a0II: Patients on dialysis (stage\u00a05). Int Urol Nephrol. 2004;36:469\u201372. https:\/\/doi.org\/10.1007\/s11255-004-6194-y","DOI":"10.1007\/s11255-004-6194-y"},{"key":"2708_CR275","doi-asserted-by":"publisher","unstructured":"Elliott AB, Soliman KMM, Ullian ME. Hyperkalemia in chronic peritoneal dialysis patients. Ren Fail. 2022;44:217\u201323. https:\/\/doi.org\/10.1080\/0886022X.2022.2032151","DOI":"10.1080\/0886022X.2022.2032151"},{"key":"2708_CR276","doi-asserted-by":"publisher","unstructured":"Fa G, Js de J, L C, Mct P, Lkrp de A, C SWM, u.\u202fa. Hypokalemia and hyperkalemia in patients on peritoneal dialysis: incidence and associated factors. Int Urol Nephrol [Internet]. Int Urol Nephrol; 2020 [zitiert 25.\u00a0Juli 2025];52. https:\/\/doi.org\/10.1007\/s11255-020-02385-2","DOI":"10.1007\/s11255-020-02385-2"},{"key":"2708_CR277","doi-asserted-by":"publisher","unstructured":"Santoro A, Mancini E, London G, Mercadal L, Fessy H, Perrone B, u.\u202fa. Patients with complex arrhythmias during and after haemodialysis suffer from different regimens of potassium removal. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2008;23:1415\u201321. https:\/\/doi.org\/10.1093\/ndt\/gfm730","DOI":"10.1093\/ndt\/gfm730"},{"key":"2708_CR278","doi-asserted-by":"publisher","unstructured":"Labriola L, Jadoul M. Sailing between Scylla and Charybdis: the high serum K\u2011low dialysate K quandary. Semin Dial. 2014;27:463\u201371. https:\/\/doi.org\/10.1111\/sdi.12252","DOI":"10.1111\/sdi.12252"},{"key":"2708_CR279","doi-asserted-by":"publisher","unstructured":"Abuelo JG. Treatment of Severe Hyperkalemia: Confronting 4 Fallacies. Kidney Int Rep. 2018;3:47\u201355. https:\/\/doi.org\/10.1016\/j.ekir.2017.10.001","DOI":"10.1016\/j.ekir.2017.10.001"},{"key":"2708_CR280","doi-asserted-by":"publisher","unstructured":"Charytan DM, Winkelmayer WC, Granger CB, Middleton JP, Herzog CA, Chertow GM, u.\u202fa. Effects of dialysate potassium concentration of 3.0\u202fmmol\/l with sodium zirconium cyclosilicate on dialysis-free days versus dialysate potassium concentration of 2.0\u202fmmol\/l alone on rates of cardiac arrhythmias in hemodialysis patients with hyperkalemia. Kidney Int. 2025;107:169\u201379. https:\/\/doi.org\/10.1016\/j.kint.2024.10.010","DOI":"10.1016\/j.kint.2024.10.010"},{"key":"2708_CR281","doi-asserted-by":"publisher","unstructured":"St-Jules DE, Goldfarb DS, Sevick MA. Nutrient Non-equivalence: Does Restricting High-Potassium Plant Foods Help to Prevent Hyperkalemia in Hemodialysis Patients? J\u00a0Ren Nutr Off J Counc Ren Nutr Natl Kidney Found. 2016;26:282\u20137. https:\/\/doi.org\/10.1053\/j.jrn.2016.02.005","DOI":"10.1053\/j.jrn.2016.02.005"},{"key":"2708_CR282","doi-asserted-by":"publisher","unstructured":"Noori N, Kalantar-Zadeh K, Kovesdy CP, Murali SB, Bross R, Nissenson AR, u.\u202fa. Dietary potassium intake and mortality in long-term hemodialysis patients. Am J Kidney Dis Off J Natl Kidney Found. 2010;56:338\u201347. https:\/\/doi.org\/10.1053\/j.ajkd.2010.03.022","DOI":"10.1053\/j.ajkd.2010.03.022"},{"key":"2708_CR283","doi-asserted-by":"publisher","unstructured":"Arnold R, Pianta TJ, Pussell BA, Kirby A, O\u2019Brien K, Sullivan K, u.\u202fa. Randomized, Controlled Trial of the Effect of Dietary Potassium Restriction on Nerve Function in CKD. Clin J Am Soc Nephrol CJASN. 2017;12:1569\u201377. https:\/\/doi.org\/10.2215\/CJN.00670117","DOI":"10.2215\/CJN.00670117"},{"key":"2708_CR284","doi-asserted-by":"publisher","unstructured":"Fishbane S, Ford M, Fukagawa M, McCafferty K, Rastogi A, Spinowitz B, u.\u202fa. A\u00a0Phase\u00a03b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia. J\u00a0Am Soc Nephrol JASN. 2019;30:1723\u201333. https:\/\/doi.org\/10.1681\/ASN.2019050450","DOI":"10.1681\/ASN.2019050450"},{"key":"2708_CR285","doi-asserted-by":"publisher","unstructured":"Ng JK\u2011C, Fung WW\u2011S, Chan GC\u2011K, Chow K\u2011M, Szeto C\u2011C. Intermittent sodium zirconium cyclosilicate for the prevention of hyperkalemia in chronic kidney disease. BMC Nephrol. 2025;26:260. https:\/\/doi.org\/10.1186\/s12882-025-04194-0","DOI":"10.1186\/s12882-025-04194-0"},{"key":"2708_CR286","doi-asserted-by":"publisher","unstructured":"Fishbane S, Dember LM, Jadoul M, Kovesdy CP, Guzman N, Kordzakhia G, u.\u202fa. The randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis. Kidney Int. 2025;S0085\u20132538(25)00509\u20115. https:\/\/doi.org\/10.1016\/j.kint.2025.06.016","DOI":"10.1016\/j.kint.2025.06.016"},{"key":"2708_CR287","doi-asserted-by":"publisher","unstructured":"Middleton JP, Sun S, Murray S, Davenport CA, Daubert JP. Randomized Trial of Patiromer on Efficacy to Reduce Episodic Hyperkalemia in Patients with ESKD Treated With Hemodialysis. Kidney Int Rep. 2024;9:3218\u201325. https:\/\/doi.org\/10.1016\/j.ekir.2024.08.005","DOI":"10.1016\/j.ekir.2024.08.005"},{"key":"2708_CR288","doi-asserted-by":"publisher","unstructured":"Kovesdy CP, Rowan CG, Conrad A, Spiegel DM, Fogli J, Oestreicher N, u.\u202fa. Real-World Evaluation of Patiromer for the Treatment of Hyperkalemia in Hemodialysis Patients. Kidney Int Rep. 2019;4:301\u20139. https:\/\/doi.org\/10.1016\/j.ekir.2018.10.020","DOI":"10.1016\/j.ekir.2018.10.020"},{"key":"2708_CR289","doi-asserted-by":"publisher","unstructured":"Mathialahan T, Sandle GI. Dietary potassium and laxatives as regulators of colonic potassium secretion in end-stage renal disease. Nephrol Dial Transplant. 2003;18:341\u20137. https:\/\/doi.org\/10.1093\/ndt\/18.2.341","DOI":"10.1093\/ndt\/18.2.341"},{"key":"2708_CR290","doi-asserted-by":"publisher","unstructured":"Nata N, Bunpeth W, Tasanavipas P, Varothai N, Supasyndh O, Satirapoj B. Effect of senna glycoside on serum potassium levels among patients on maintenance hemodialysis: A\u00a0randomized controlled trial. Ther Apher Dial. 2022;26:908\u201314. https:\/\/doi.org\/10.1111\/1744-9987.13774","DOI":"10.1111\/1744-9987.13774"},{"key":"2708_CR291","doi-asserted-by":"publisher","unstructured":"Sibbel S, Walker AG, Colson C, Tentori F, Brunelli SM, Flythe J. Association of Continuation of Loop Diuretics at Hemodialysis Initiation with Clinical Outcomes. Clin J Am Soc Nephrol. 2019;14:95. https:\/\/doi.org\/10.2215\/CJN.05080418","DOI":"10.2215\/CJN.05080418"},{"key":"2708_CR292","doi-asserted-by":"publisher","unstructured":"Bragg-Gresham JL, Fissell RB, Mason NA, Bailie GR, Gillespie BW, Wizemann V, u.\u202fa. Diuretic Use, Residual Renal Function, and Mortality Among Hemodialysis Patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS). Am J Kidney Dis. 2007;49:426\u201331. https:\/\/doi.org\/10.1053\/j.ajkd.2006.12.012","DOI":"10.1053\/j.ajkd.2006.12.012"},{"key":"2708_CR293","doi-asserted-by":"publisher","unstructured":"Schambelan M, Sebastian A, Biglieri EG, Brust NL, Chang BC, Hirai J, u.\u202fa. Prevalence, pathogenesis, and functional significance of aldosterone deficiency in hyperkalemic patients with chronic renal insufficiency. Kidney Int. 1980;17:89\u2013101. https:\/\/doi.org\/10.1038\/ki.1980.11","DOI":"10.1038\/ki.1980.11"},{"key":"2708_CR294","doi-asserted-by":"publisher","unstructured":"Kaisar MO, Wiggins KJ, Sturtevant JM, Hawley CM, Campbell SB, Isbel NM, u.\u202fa. A\u00a0randomized controlled trial of fludrocortisone for the treatment of hyperkalemia in hemodialysis patients. Am J Kidney Dis Off J Natl Kidney Found. 2006;47:809\u201314. https:\/\/doi.org\/10.1053\/j.ajkd.2006.01.014","DOI":"10.1053\/j.ajkd.2006.01.014"},{"key":"2708_CR295","doi-asserted-by":"publisher","unstructured":"Allon M. Hyperkalemia in end-stage renal disease: mechanisms and management. J\u00a0Am Soc Nephrol JASN. 1995;6:1134\u201342. https:\/\/doi.org\/10.1681\/ASN.V641134","DOI":"10.1681\/ASN.V641134"},{"key":"2708_CR296","doi-asserted-by":"publisher","unstructured":"Epstein M. Hyperkalemia constitutes a\u00a0constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena. Kidney Int Suppl. 2016;6:20\u20138. https:\/\/doi.org\/10.1016\/j.kisu.2016.01.004","DOI":"10.1016\/j.kisu.2016.01.004"},{"key":"2708_CR297","doi-asserted-by":"publisher","unstructured":"Trevisan M, Fu EL, Xu Y, Savarese G, Dekker FW, Lund LH, u.\u202fa. Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care. Eur J Heart Fail. 2021;23:1698\u2013707. https:\/\/doi.org\/10.1002\/ejhf.2287","DOI":"10.1002\/ejhf.2287"},{"key":"2708_CR298","doi-asserted-by":"publisher","unstructured":"Fu EL, Evans M, Clase CM, Tomlinson LA, van Diepen M, Dekker FW, u.\u202fa. Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A\u00a0Nationwide Study. J\u00a0Am Soc Nephrol JASN. 2021;32:424\u201335. https:\/\/doi.org\/10.1681\/ASN.2020050682","DOI":"10.1681\/ASN.2020050682"},{"key":"2708_CR299","doi-asserted-by":"publisher","unstructured":"Pitt B, Anker SD, Lund LH, Coats AJS, Filippatos G, Rossignol P, u.\u202fa. Patiromer Facilitates Angiotensin Inhibitor and Mineralocorticoid Antagonist Therapies in Patients With Heart Failure and Hyperkalemia. J\u00a0Am Coll Cardiol. 2024;84:1295\u2013308. https:\/\/doi.org\/10.1016\/j.jacc.2024.05.079","DOI":"10.1016\/j.jacc.2024.05.079"},{"key":"2708_CR300","doi-asserted-by":"publisher","unstructured":"Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang I\u2011Z, u.\u202fa. Evaluation of the efficacy and safety of RLY5016, a\u00a0polymeric potassium binder, in a\u00a0double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011;32:820\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/ehq502","DOI":"10.1093\/eurheartj\/ehq502"},{"key":"2708_CR301","doi-asserted-by":"publisher","unstructured":"Agarwal R, Rossignol P, Mayo MR, Conrad A, Arthur S, Williams B, u.\u202fa. Patiromer to Enable Spironolactone in Patients with Resistant Hypertension and CKD (AMBER): Results in the Prespecified Subgroup with Diabetes. Clin J Am Soc Nephrol CJASN. 2021;16:1407\u20139. https:\/\/doi.org\/10.2215\/CJN.02890221","DOI":"10.2215\/CJN.02890221"},{"key":"2708_CR302","doi-asserted-by":"publisher","unstructured":"Agiro A, An A, Cook EE, Mu F, Chen J, Desai P, u.\u202fa. Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study. Adv Ther. 2023;40:2886\u2013901. https:\/\/doi.org\/10.1007\/s12325-023-02518-w","DOI":"10.1007\/s12325-023-02518-w"},{"key":"2708_CR303","doi-asserted-by":"publisher","unstructured":"Agiro A, Greatsinger A, Mu F, Cook EE, Chen J, Sundar M, u.\u202fa. Renin-Angiotensin-Aldosterone System Inhibitor Dosing After Initiation of Outpatient Sodium Zirconium Cyclosilicate Therapy: The GALVANIZE RAASi Real-World Evidence Study. Adv Ther. 2025; https:\/\/doi.org\/10.1007\/s12325-025-03254-z","DOI":"10.1007\/s12325-025-03254-z"},{"key":"2708_CR304","doi-asserted-by":"publisher","unstructured":"Ash SR, Singh B, Lavin PT, Stavros F, Rasmussen HS. A\u00a0phase\u00a02\u00a0study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS\u20119, is safe and efficient. Kidney Int. 2015;88:404\u201311. https:\/\/doi.org\/10.1038\/ki.2014.382","DOI":"10.1038\/ki.2014.382"},{"key":"2708_CR305","doi-asserted-by":"publisher","unstructured":"Kovesdy CP, Gosmanova EO, Woods SD, Fogli JJ, Rowan CG, Hansen JL, u.\u202fa. Real-world management of hyperkalemia with patiromer among United States Veterans. Postgrad Med. 2020;132:176\u201383. https:\/\/doi.org\/10.1080\/00325481.2019.1706920","DOI":"10.1080\/00325481.2019.1706920"},{"key":"2708_CR306","doi-asserted-by":"publisher","unstructured":"Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med. 1998;158:26\u201332. https:\/\/doi.org\/10.1001\/archinte.158.1.26","DOI":"10.1001\/archinte.158.1.26"},{"key":"2708_CR307","doi-asserted-by":"publisher","unstructured":"Desai AS, Vardeny O, Claggett B, McMurray JJV, Packer M, Swedberg K, u.\u202fa. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril\/Valsartan Compared With Enalapril: A\u00a0Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2017;2:79\u201385. https:\/\/doi.org\/10.1001\/jamacardio.2016.4733","DOI":"10.1001\/jamacardio.2016.4733"},{"key":"2708_CR308","doi-asserted-by":"publisher","unstructured":"Wing S, Ray JG, Yau K, Jeyakumar N, Abdullah S, Luo B, u.\u202fa. SGLT2 Inhibitors and Risk for Hyperkalemia Among Individuals Receiving RAAS Inhibitors. JAMA Intern Med. 2025;e250686. https:\/\/doi.org\/10.1001\/jamainternmed.2025.0686","DOI":"10.1001\/jamainternmed.2025.0686"},{"key":"2708_CR309","doi-asserted-by":"publisher","unstructured":"Luo X, Xu J, Zhou S, Xue C, Chen Z, Mao Z. Influence of SGLT2i and RAASi and Their Combination on Risk of Hyperkalemia in DKD: A\u00a0Network Meta-Analysis. Clin J Am Soc Nephrol CJASN. 2023;18:1019\u201330. https:\/\/doi.org\/10.2215\/CJN.0000000000000205","DOI":"10.2215\/CJN.0000000000000205"},{"key":"2708_CR310","doi-asserted-by":"publisher","unstructured":"Nie S, Li Y, Sun Y, Chen S, Shao X, Pang M, u.\u202fa. Discontinuation of Renin-Angiotensin System Inhibitors during Acute Kidney Injury Episode and All-Cause Mortality: Target Trial Emulation Studies. J\u00a0Am Soc Nephrol JASN. 2025; https:\/\/doi.org\/10.1681\/ASN.0000000775","DOI":"10.1681\/ASN.0000000775"},{"key":"2708_CR311","unstructured":"Optimization of RAASi Therapy Toolkit [Internet]. Int. Soc. Nephrol. [zitiert 27.\u00a0Juli 2025]. https:\/\/www.theisn.org\/initiatives\/toolkits\/raasi-toolkit\/. Zugegriffen 27\u00a0Juli 2025"},{"key":"2708_CR312","doi-asserted-by":"publisher","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, u.\u202fa. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2019;381:1609\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1908655","DOI":"10.1056\/NEJMoa1908655"},{"key":"2708_CR313","doi-asserted-by":"publisher","unstructured":"Butler J, Anker SD, Lund LH, Coats AJS, Filippatos G, Siddiqi TJ, u.\u202fa. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J. 2022;43:4362\u201373. https:\/\/doi.org\/10.1093\/eurheartj\/ehac401","DOI":"10.1093\/eurheartj\/ehac401"},{"key":"2708_CR314","doi-asserted-by":"publisher","unstructured":"Kosiborod MN, Cherney DZI, Desai AS, Testani JM, Verma S, Chinnakondepalli K, u.\u202fa. Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart Failure. J\u00a0Am Coll Cardiol. 2025;85:971\u201384. https:\/\/doi.org\/10.1016\/j.jacc.2024.11.014","DOI":"10.1016\/j.jacc.2024.11.014"},{"key":"2708_CR315","doi-asserted-by":"publisher","unstructured":"Tardif J\u2011C, Rouleau J, Chertow GM, Al-Shurbaji A, Lisovskaja V, Gustavson S, u.\u202fa. Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure. ESC Heart Fail. 2023;10:1066\u201376. https:\/\/doi.org\/10.1002\/ehf2.14268","DOI":"10.1002\/ehf2.14268"},{"key":"2708_CR316","doi-asserted-by":"publisher","unstructured":"Gregg LP, Navaneethan SD. Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders? Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2023;38:1355\u201365. https:\/\/doi.org\/10.1093\/ndt\/gfac284","DOI":"10.1093\/ndt\/gfac284"},{"key":"2708_CR317","doi-asserted-by":"publisher","unstructured":"Packer M. Do Potassium Binders Block Both the Benefits and the Risks of Mineralocorticoid Receptor Antagonists in Heart Failure?: The Four Anti-Aldosterone Myths. J\u00a0Am Coll Cardiol. 2025;85:985\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2025.01.011","DOI":"10.1016\/j.jacc.2025.01.011"},{"key":"2708_CR318","doi-asserted-by":"publisher","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, u.\u202fa. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"2708_CR319","doi-asserted-by":"publisher","unstructured":"Savarese G, Izquierdo MJ, Bonanad C, Wong A, Schmitt R, Ferraro PM, u.\u202fa. Interdisciplinary recommendations for recurrent hyperkalaemia: Insights from the GUARDIAN-HK European Steering Committee. Eur Heart J Cardiovasc Pharmacother. 2025;pvaf055. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf055","DOI":"10.1093\/ehjcvp\/pvaf055"},{"key":"2708_CR320","doi-asserted-by":"publisher","unstructured":"Shen L, Kristensen SL, Bengtsson O, B\u00f6hm M, de Boer RA, Docherty KF, u.\u202fa. Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF. JACC Heart Fail. 2021;9:254\u201364. https:\/\/doi.org\/10.1016\/j.jchf.2020.11.009","DOI":"10.1016\/j.jchf.2020.11.009"},{"key":"2708_CR321","doi-asserted-by":"publisher","unstructured":"Ferreira JP, Zannad F, Butler J, Filipattos G, Ritter I, Sch\u00fcler E, u.\u202fa. Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled. Eur Heart J. 2022;43:2984\u201393. https:\/\/doi.org\/10.1093\/eurheartj\/ehac306","DOI":"10.1093\/eurheartj\/ehac306"},{"key":"2708_CR322","doi-asserted-by":"publisher","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, u.\u202fa. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020;382:1883\u201393. https:\/\/doi.org\/10.1056\/NEJMoa1915928","DOI":"10.1056\/NEJMoa1915928"},{"key":"2708_CR323","doi-asserted-by":"publisher","unstructured":"Hironaka J, Okada H, Osaka T, Hashimoto Y, Kobayashi G, Tanaka M, u.\u202fa. Non-inferiority of sodium zirconium cyclosilicate versus potassium-restricted diet in achieving normokalaemia in patients with type\u00a02 diabetes mellitus: protocol for a\u00a0multicentre, open-label, randomised controlled, two-arm clinical trial (SILVERSTAR study). British Medical Journal Publishing Group; 2025 [zitiert 27.\u00a0Juli 2025]; https:\/\/doi.org\/10.1136\/bmjopen-2024-089564","DOI":"10.1136\/bmjopen-2024-089564"},{"key":"2708_CR324","doi-asserted-by":"publisher","unstructured":"Sebastian A, Schambelan M, Sutton JM. Amelioration of hyperchloremic acidosis with furosemide therapy in patients with chronic renal insufficiency and type\u00a04 renal tubular acidosis. Am J Nephrol. 1984;4:287\u2013300. https:\/\/doi.org\/10.1159\/000166827","DOI":"10.1159\/000166827"},{"key":"2708_CR325","doi-asserted-by":"publisher","unstructured":"Palmer BF, Clegg DJ. Electrolyte and Acid-Base Disturbances in Patients with Diabetes Mellitus. N Engl J Med. 2015;373:548\u201359. https:\/\/doi.org\/10.1056\/NEJMra1503102","DOI":"10.1056\/NEJMra1503102"},{"key":"2708_CR326","doi-asserted-by":"publisher","unstructured":"Sebastian A, Schambelan M, Lindenfeld S, Morris RC. Amelioration of metabolic acidosis with fludrocortisone therapy in hyporeninemic hypoaldosteronism. N Engl J Med. 1977;297:576\u201383. https:\/\/doi.org\/10.1056\/NEJM197709152971104","DOI":"10.1056\/NEJM197709152971104"},{"key":"2708_CR327","doi-asserted-by":"publisher","unstructured":"Hahner S, Ross RJ, Arlt W, Bancos I, Burger-Stritt S, Torpy DJ, u.\u202fa. Adrenal insufficiency. Nat Rev Dis Primer. 2021;7:19. https:\/\/doi.org\/10.1038\/s41572-021-00252-7","DOI":"10.1038\/s41572-021-00252-7"},{"key":"2708_CR328","doi-asserted-by":"publisher","unstructured":"Zieg J, Thomasov\u00e1 D, Libik M, Sumnik Z, Bockenhauer D. Hyperkalaemic acidosis: blood pressure is the diagnostic clue. Pediatr Nephrol Berl Ger. 2025;40:967\u201370. https:\/\/doi.org\/10.1007\/s00467-024-06590-4","DOI":"10.1007\/s00467-024-06590-4"},{"key":"2708_CR329","doi-asserted-by":"publisher","unstructured":"Bandhakavi M, Wanaguru A, Ayuk L, Kirk JM, Barrett TG, Kershaw M, u.\u202fa. Clinical characteristics and treatment requirements of children with autosomal recessive pseudohypoaldosteronism. Eur J Endocrinol. 2021;184:K15\u201320. https:\/\/doi.org\/10.1530\/EJE-20-0152","DOI":"10.1530\/EJE-20-0152"},{"key":"2708_CR330","doi-asserted-by":"publisher","unstructured":"Furuland H, McEwan P, Evans M, Linde C, Ayoubkhani D, Bakhai A, u.\u202fa. Serum potassium as a\u00a0predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink. BMC Nephrol. 2018;19:211. https:\/\/doi.org\/10.1186\/s12882-018-1007-1","DOI":"10.1186\/s12882-018-1007-1"},{"key":"2708_CR331","doi-asserted-by":"publisher","unstructured":"Davis J, Israni R, Mu F, Cook EE, Szerlip H, Uwaifo G, u.\u202fa. Inpatient management and post-discharge outcomes of hyperkalemia. Hosp Pract 1995. 2021;49:273\u20139. https:\/\/doi.org\/10.1080\/21548331.2021.1925554","DOI":"10.1080\/21548331.2021.1925554"},{"key":"2708_CR332","doi-asserted-by":"publisher","unstructured":"Jun H\u2011R, Kim H, Lee S\u2011H, Cho JH, Lee H, Yim HW, u.\u202fa. Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin\u00a0II Receptor Blocker. Cardiovasc Ther. 2021;2021:5935149. https:\/\/doi.org\/10.1155\/2021\/5935149","DOI":"10.1155\/2021\/5935149"},{"key":"2708_CR333","doi-asserted-by":"publisher","unstructured":"Crop MJ, Hoorn EJ, Lindemans J, Zietse R. Hypokalaemia and subsequent hyperkalaemia in hospitalized patients. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2007;22:3471\u20137. https:\/\/doi.org\/10.1093\/ndt\/gfm471","DOI":"10.1093\/ndt\/gfm471"},{"key":"2708_CR334","doi-asserted-by":"publisher","unstructured":"J\u00f8nsson SS, S\u00f8rensen SA, Kr\u00f8gh ST, Melgaard D, S\u00f8gaard P, S\u00f8ndergaard MM, u.\u202fa. Short-term prognosis of changes in plasma potassium following an episode of hyperkalaemia in patients with chronic heart failure. Eur J Intern Med. 2023;118:82\u20138. https:\/\/doi.org\/10.1016\/j.ejim.2023.07.031","DOI":"10.1016\/j.ejim.2023.07.031"},{"key":"2708_CR335","doi-asserted-by":"publisher","unstructured":"Hutter T, Collings TS, Kostova G, Karet Frankl FE. Point-of-care and self-testing for potassium: recent advances. Sens Diagn. 2022;1:614\u201326. https:\/\/doi.org\/10.1039\/d2sd00062h","DOI":"10.1039\/d2sd00062h"},{"key":"2708_CR336","doi-asserted-by":"publisher","unstructured":"Bamforth RJ, Ferguson TW, Tangri N, Rigatto C, Collister D, Komenda P. Cost-Utility of Real-Time Potassium Monitoring in United States Patients Receiving Hemodialysis. Kidney Int Rep. 2024;9:3226\u201335. https:\/\/doi.org\/10.1016\/j.ekir.2024.08.007","DOI":"10.1016\/j.ekir.2024.08.007"},{"key":"2708_CR337","doi-asserted-by":"publisher","unstructured":"Kuo W\u2011H, You H\u2011L, Huang W\u2011T, Lee Y\u2011T, Chiou TT\u2011Y, Ng H\u2011Y, u.\u202fa. Incidence, characteristics and outcomes among inpatient, outpatient and emergency department with reported high critical serum potassium values. Clin Chem Lab Med. 2021;59:1231\u20137. https:\/\/doi.org\/10.1515\/cclm-2020-1476","DOI":"10.1515\/cclm-2020-1476"},{"key":"2708_CR338","doi-asserted-by":"publisher","unstructured":"Drumheller BC, Tuffy E, Gibney F, Stallard S, Siewers C, Korvek S. Severe bradycardia from severe hyperkalemia: Patient characteristics, outcomes and factors associated with hemodynamic support. Am J Emerg Med. 2022;55:117\u201325. https:\/\/doi.org\/10.1016\/j.ajem.2022.03.007","DOI":"10.1016\/j.ajem.2022.03.007"},{"key":"2708_CR339","doi-asserted-by":"publisher","unstructured":"An JN, Lee JP, Jeon HJ, Kim DH, Oh YK, Kim YS, u.\u202fa. Severe hyperkalemia requiring hospitalization: predictors of mortality. Crit Care Lond Engl. 2012;16:R225. https:\/\/doi.org\/10.1186\/cc11872","DOI":"10.1186\/cc11872"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-026-02708-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-026-02708-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-026-02708-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:11:15Z","timestamp":1773328275000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-026-02708-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":339,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2708"],"URL":"https:\/\/doi.org\/10.1007\/s00508-026-02708-w","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.\u00a0Windpessl, M.\u00a0Saemann, A.\u00a0Kirsch, R.\u00a0Edlinger: Vortragshonorare von Astra Zeneca und CSL Vifor. M.\u00a0Pirklbauer: Reisekostenunterst\u00fctzung und Vortragshonorare von Astra Zeneca und CSL Vifor. S.H.\u00a0Ksiazek: Vortragshonorare von Astra Zeneca. G.\u00a0Lindner und C.\u00a0Schwarz geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}